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ABSTRACT OF DISSERTATION

EXPLORING THE EFFECT OF CHRONIC INFLAMMATION ON RESPONSE
TO IMMUNE CHECKPOINT INHIBITORS IN CANCER
Precision medicine has allowed for the development of monoclonal antibodies that
unmask the anti-tumor immune response. These agents have provided some patients
durable clinical benefit. However, PD-1 and PD-L1 inhibitor therapies are effective in a
small group (10-20%) of non-small cell lung cancer (NSCLC) patients when used as
single-agent therapy. The approved companion diagnostic is expression of the immune
cell surface molecule, programmed death ligand 1 (PD-L1), on tumors measured by
immunohistochemistry (IHC). Studies in tumor biology and immune surveillance dictate
that PD-1 inhibitor efficacy should depend on the level of PD-L1 expression; however,
the literature has not followed with convincing evidence. The limitations of this test
include timing of tissue acquisition, tumor heterogeneity, and timing of therapy relative to
the expression of PD-L1. In addition, the requirement of analyzing tumor tissue biopsy
samples from a patient is cumbersome. Thus, a peripheral blood biomarker that predicts
efficacy of PD-1/PD-L1 inhibition would be optimal for precise and cost-effective
treatment. A history of chronic inflammatory diseases may be advantageous for a cancer
patient who is treated with PD-1/PD-L1 inhibitors and may allow them to then mobilize a
swift immune response to tumor cells. Specific biological components of this persistent
inflammation may predict PD-1 inhibitor response. We have taken a novel approach to
leverage national healthcare claims data that couples patient history with response to
therapy. We have identified potential peripheral blood biomarkers of response to PD1/PD-L1 inhibitors using a combination of healthcare outcomes and molecular markers
that correlate with therapeutic efficacy.

KEYWORDS: Immune checkpoint inhibitors, biomarkers of response, health outcomes
research, cancer, PD-1/PD-L1

__Sherif M. El-Refai, Pharm.D, M.B.A._____
Student’s Signature
_December 15th, 2017__________________
Date

EXPLORING THE EFFECT OF CHRONIC INFLAMMATION ON RESPONSE TO
IMMUNE CHECKPOINT INHIBITORS IN CANCER
By:
Sherif M. El-Refai, Pharm.D, M.B.A

Esther P. Black, Ph.D.
Co-Director of Dissertation

Jeffery Talbert, Ph.D.
Co-Director of Dissertation

Dave Feola, Pharm.D, Ph.D.
Director of Graduate Studies

December 15th, 2017
Date

ACKNOWLEDGEMENTS

The following dissertation could not have been completed without the guidance,
encouragement and aid of many of my peers, colleagues and mentors. First, and
foremost, my advisor and co-committee chair, Dr. Penni Black devoted a tremendous
amount of time shaping my skillsets, being my closest advocate and guiding me into a
career of translational medicine. Dr. Jeffery Talbert provided me novel opportunities in a
new research space expanding my understanding of what it means to be a translational
scientist. Dr. Val Adams placed clinical applicability into the forethought of my brain and
ensured that I always had the patient in mind. Dr. John Yannelli continually pushed and
challenged me to develop my own insights into the scientific method. I would also like to
acknowledge Dr. Katherine Thompson for her expertise in statistical analyses and
spending countless hours assisting me in quantifying results from our data. I would like
to thank the center for clinical and translational services and the Markey Cancer Center
for which much of this work would not be possible. Most importantly, I would like to thank
my family for supporting my endeavors no matter how far or how long they have taken
me.

iii

Table of Contents
Acknowledgements .......................................................................................................... iii
List of Tables .................................................................................................................... vi
List of Figures .................................................................................................................. vii
Chapter 1 .......................................................................................................................... 1
A.

CANCER & THE IMMUNE RESPONSE OVERVIEW ........................................ 1

B.

CANCER IMMUNOTHERAPY ............................................................................ 9

C.

TUMOR BIOMARKERS OF RESPONSE ......................................................... 11

D.

BIOMARKERS OF RESPONSE IN PERIPHERAL BLOOD ............................. 20

E.

RESEARCH PROPOSAL OVERVIEW ............................................................. 25

Chapter 2 ........................................................................................................................ 31
A.

OVERVIEW ...................................................................................................... 31

B.

METHODS ........................................................................................................ 33

C.

RESULTS ......................................................................................................... 36

D.

DISCUSSION ................................................................................................... 48

E.

CONCLUSION .................................................................................................. 51

Chapter 3 ........................................................................................................................ 52
A.

OVERVIEW ...................................................................................................... 52

B.

METHODS ........................................................................................................ 53

C.

RESULTS ......................................................................................................... 54

D.

CONCLUSION .................................................................................................. 60

Chapter 4 ........................................................................................................................ 61
A.

OVERVIEW ...................................................................................................... 61

B.

METHODS ........................................................................................................ 67

C.

RESULTS ......................................................................................................... 72

D.

DISCUSSION ................................................................................................... 82

E.

CONCLUSIONS ................................................................................................ 88

Chapter 5 ........................................................................................................................ 90
A.

OVERVIEW ...................................................................................................... 90

B.

METHODS ........................................................................................................ 92

C.

RESULTS ......................................................................................................... 98

D.

DISCUSSION ................................................................................................. 105

E.

CONCLUSION ................................................................................................ 107

Chapter 6 ...................................................................................................................... 109
A.

SUMMARY OF RESULTS .............................................................................. 109
iv

A.

EXPERIMENTAL CONSIDERATIONS ........................................................... 111

B.

CONTRIBUTION TO THE FIELD ................................................................... 113

C.

TRANSLATIONAL AND CLINICAL RELEVANCE .......................................... 114

D.

CONCLUSIONS ............................................................................................. 116

REFERENCES .............................................................................................................. 117
VITA .............................................................................................................................. 133

v

LIST OF TABLES
Table 1.1: Overview of candidate biomarkers of response for immune checkpoint
inhibitors. ......................................................................................................................... 27
Table 2.1: Baseline demographic and clinical characteristics of all cohorts included in
the analysis. .................................................................................................................... 38
Table 2.2: Age sensitivity analysis for all exposure group analyses. ............................. 44
Table 3.1: Autoimmune (AI) disorders in lung and renal cancer patients between the
years 2009-2013. ............................................................................................................ 56
Table 3.2: Baseline characteristics and comorbidities between lung and renal cancer
patients with or without autoimmune disease. ................................................................ 58
Table 4.1: PD-L1 expression and history of inflammation for nivolumab-treated NSCLC
patients............................................................................................................................ 76
Table 4.2: Baseline demographics for all immune checkpoint inhibitor treated patients.
........................................................................................................................................ 79
Table 4.3: Standardized differences post-propensity score matching............................ 80
Table 4.4: One-year survival analysis for ICI-treated patients.. ...................................... 81
Table 5.1: Cytokine measurements organized by cohort. .............................................. 99

vi

LIST OF FIGURES
Figure 1.1: Normal adaptive immune response to tumor associated antigens (TAAs) .... 4
Figure 1.2: Mechanisms of tumor immune evasion........................................................... 8
Figure 2.1: CONSORT flow diagram. .............................................................................. 40
Figure 2.2: One-year survival analysis ........................................................................... 42
Figure 2.3: The effect of dose intensity on one-year survival .......................................... 43
Figure 2.4: The effect of statin stratification by type and class on one-year survival ..... 46
Figure 2.5: The effect of synergistic statin combinations on one-year survival .............. 47
Figure 4.1: Health outcomes data analysis timeline and process. ................................. 70
Figure 4.2: MCC nivolumab-treated patients treated March 2015 to February 2016. ..... 73
Figure 4.3: The effect of chronic inflammatory conditions on cycles of nivolumab. ....... 74
Figure 5.1: Clinical study protocol .................................................................................. 97
Figure 5.2: Comparison of IL-4, IL-6, IL-13, IL-23, IFN-γ, and TNF-α levels by cohort.
...................................................................................................................................... 100
Figure 5.3: Comparison of immune cell populations by cohort. ................................... 103
Figure 5.4: Feasible solutions algorithm (FSA) assessment to predict durable response
in NSCLC cohort. ......................................................................................................... 104

vii

CHAPTER 1
A. CANCER & THE IMMUNE RESPONSE OVERVIEW
Cancer Overview
Cancer is understood to be a disease of unchecked cell growth due to genetic mutation;
a continuous series of genetic events that guide cells to uncontrolled proliferation and
invasion into surrounding tissue. Tumor cells gain the ability to survive independently
and metastasize to other organs within the body (1). Multiple organ involvement and
ultimate failure is the final state of late-stage disease, resulting in death. Standard of
care for cancer includes the resection of the malignant tissue, radiotherapy, and
systemic chemotherapy. Resection of the malignancy, the only treatment which can be
considered a cure among solid tumors, is typically only possible when the disease is
localized and detected early (2). Unfortunately, patients with aggressive cancer types,
including lung cancer, are diagnosed during late stage disease resulting in high mortality
rates (3). Hanahan and Weinberg published the first iteration of The Hallmarks of Cancer
in the year 2000 wherein they described six major factors influencing cancer biology;
self-sufficiency in growth signals, insensitivity to anti-growth signals, evading apoptosis,
limitless replicative potential, sustained angiogenesis, and tissue invasion and
metastasis (1). Specifically, normal cells require mitogens to signal them to undergo
growth and division; however, cancer cells are often able to grow despite the lack of
external signals. Tumor suppressor genes are expressed to halt division in normal cells;
however, cancer cells harbor mutated tumor suppressor genes resulting in aberrant
progression through the cell cycle. Apoptosis is the programmed self-destruct function of
nucleated cells to prevent the formation of abnormalities such as aberrant growth.
Cancer cells can evade this programming. Normal cells have a finite number of divisions
before a cell becomes unable to divide, known as senescence. Cancer cells overcome
1

this limit by disabling the pRB, p53 tumor suppressor proteins and maintaining
telomeres. Angiogenesis is the generation of new blood vessels from pre-existing
vessels and is essential for the transportation of oxygen. New blood vessels are typically
generated during wound repair and the development of embryos; however, cancer cells
can trigger the production of new vasculature. Lastly, cancer cells can undergo
transformation from an epithelial form to mesenchymal form to break away from the
primary tumor site to metastasize to distant organs. In 2011, Hanahan and Weinberg
supported the inclusion of four additional hallmarks; reprogramming of energy
metabolism, genome instability, inflammation and evading the immune response (4).
Specifically, cancer cells prevent mitochondria from normal aerobic respiration leading to
the decreased production of ATP. The resulting low ATP: ADP ratio deactivates
mitochondria and prevents triggering of apoptosis. Cancer cells can harbor
chromosomal abnormalities such as tetraploidy or trisomy making DNA more susceptible
to mutations. Local chronic inflammation can, over time, cause DNA damage leading to
the development of cancer cells. The discovery that cancer cells use mechanisms to
evade the immune response initiated investigations into medications that would retarget
the immune response to cancer.

Cancer immunosurveillance describes a mechanism by which tumor cells are
recognized and subsequently destroyed by the immune system (5, 6). Exploitation of
immune mechanisms and evasion of immune surveillance are activities that survived
selection in cells that underwent random mutagenesis to ensure the rise of a tumor.
Tumor-associated antigens (TAAs) as well as neoantigens released by the cancer cells
enter the blood circulation and initiate the triggering of the immune response (Figure
1.1). The tumor microenvironment contains multiple immune cell-types, including
macrophages, dendritic cells, natural killer (NK) cells, mast cells, B cells, and T cells
2

including T helper 1 (Th1) CD4+, T helper 2 (Th2) CD4+, regulatory T cells (TReg) and
cytotoxic CD8+ T cells (7). The presence of the immune cells as well as cytokines and
chemokines in the tumor microenvironment aid the growth and viability of the cancer
cell. The immune response is differentiated into two types: the innate immune response
and the adaptive immune response. The immune cells that are part of the innate
response include dendritic cells, macrophages, NK cells and mast cells that are the first
to respond to foreign agents. These cells, however, are not specially targeted for the
cancer cells. The adaptive response typically follows the innate response. Its potency
and effectiveness is greater than the innate response due to the priming and activation
of these cells for the specific target. Certain adaptive immune cells can exert anti-tumor
effects by recognizing TAAs or neoantigens presented on major histocompatibility
complex (MHC) molecules (Figure 1.1). These antigens are presented to T cells via
MHC class I or MHC class II on antigen presenting cells (APC) within lymph nodes. The
presentation of the antigen requires additional co-stimulatory signals to induce T cell
activation and expansion. Binding of B7 (CD80/CD86) on the APC to CD28 on the T cell
leads to proliferation and differentiation via production of cytokines including interleukin
(IL)-2. The effect is to drive clonal expansion of the activated T cell and to recruit other
immune effector cells. Th1 and Th2 T cells secrete cytokines and chemokines that help
to regulate this process with Th1 T cells activating CD8+ T cells and Th2 cells activating
B cells. The primed T cells then exit the lymph node and are trafficked to the tumor site
infiltrating the tumor. The cancer cells can then be destroyed by direct cell-mediated
cytotoxicity. This adaptive immune response limits the establishment of cancer.
However, in some cases tumor cells can escape the selective pressure from the immune
system that allow tumor progression in the face of an ongoing immune response (8, 9).

3

Figure 1.1: Normal adaptive immune response to tumor associated antigens (TAAs).
Used with permission from Macmillan Publishers Ltd: Nature Reviews Cancer, 6, 24-37,
copyright 2006.
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Selection of tumor cells with the ability to increase the expression of certain markers that
alter natural immune defenses of the host is favored, protecting themselves from
destruction. Specifically, many tumors acquire the ability to modify cell surface epitopes
and upregulate immune checkpoint molecules such as cytotoxic T-lymphocyteassociated protein 4 (CTLA-4), programmed death-ligand 1 (PD-L1), lymphocyte
activation gene 3 protein (LAG-3), and T cell immunoglobulin domain and mucin domaincontaining protein 3 (TIM-3), thereby resisting an immune response (9-11). Programmed
death cell protein 1 (PD-1), is normally expressed on CD4+ or CD8+ T cells. Antigen
presenting cells (APC) normally express PD-L1 that, when bound by PD-1 on T cells,
signal an exhausted active immune response. Evaluation of T cells in the tumor
microenvironment show that these cells are often in the exhausted state leading to
cancer immune evasion (Figure 1.2) (12). A growing approach to cancer therapy is the
development of agents that block these immunosuppressive mechanisms by interfering
with these checkpoint sites.
Immune Response Deregulation
Naïve T cells undergo maturity in response to acute events such as bacterial/viral
infections or vaccinations over a 1-2 week period resulting in differentiation into T cells
with effector functions (13, 14). Following clonal expansion and the clearance of the
foreign antigen, a subset of T cells remain and become memory T cells. This pool of
memory T cells retains the ability to rapidly reactivate effector functions against any
future recurrence of the stimulating antigen. However, these functional, persistent
memory T cells mature in the absence of continual antigen stimulation and after
inflammation from the effector phase has subsided.

In stark contrast, chronic conditions, such as cancer, involve persistent antigen exposure
and chronic inflammation which then alters the development of memory T cells (15-17).
5

The alteration of these memory T cells, known as T cell exhaustion, includes key
characteristics such as sustained upregulation and co-expression of multiple inhibitory
receptors. Another characteristic of T cell exhaustion is the loss of secreted cytokine
including interleukin-2 (IL-2), interferon gamma (IFN-γ) and tumor necrosis factor alpha
(TNFα) (18, 19). T cells in this hypo-responsive state have been described in multiple
conditions, including chronic viral infections such as lymphocytic choriomeningitis virus
(LCMV), HIV and hepatitis C virus, in addition to cancer (20). Overexpression of
inhibitory receptors PD-1 and CTLA-4, can be reversed to allow the immune response
against these conditions (20, 21). The molecular mechanisms by which inhibitory
receptors regulate T cell exhaustion remain unknown; however, there are several
mechanisms discussed in the literature. First, inhibitory receptors may block target
receptors or ligands preventing the formation of lipid rafts, as has been shown with
CTLA-4 (22). Second, modulation of intracellular mediators downstream of receptor
signaling can lessen the influence of activating signals from receptors such as TCR and
co-stimulatory receptors (23). Lastly, induction of inhibitory genes such as basic leucine
transcription factor, ATF-like (BATF) may lead to T cell exhaustion (24).

There are several cell surface interactions that mediate T cell exhaustion (Figure 1.2).
Upon T cell activation due to an acute event, PD-1 expression is upregulated; however,
during chronic infections, co-expression of other cell surface inhibitory molecules such
LAG-3, CD160, TIM-3 and CTLA-4 has been observed [(25, 26). LAG-3 is a cell surface
protein that is structurally homologous to CD4 and binds to MHCII, inhibiting CD4dependent downstream signaling (27). Immune checkpoints, consisting of stimulatory or
inhibitory signals, regulate T cell activation and effector functions to sustain selftolerance and minimize normal tissue damage (28). Blockade of more than one immune
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checkpoint, such as PD-1 and LAG-3, results in improved reversal of T cell exhaustion
(25, 29, 30).

In addition to the immune checkpoint receptors and proteins expressed on immune cell
components, certain soluble factors found in the tumor microenvironment and periphery
that also play a role in the induction and suppression of the exhausted T cells.
Overexpression of inflammatory or immunosuppressive cytokines that induce T cell
exhaustion are important soluble factors. Chronic interferon alpha and interferon beta
(IFN-α/β) signaling has been shown to induce T cell exhaustion during chronic infection
(31). IL-10 blockade has been shown to restore T cell function during chronic viral
infections (32). Certain cytokines, such as IL-6 and IL-27, induce the exhausted T cell
phenotype (33, 34). In addition, blockade of PD-1 and IL-10 simultaneously in mice
synergistically reverses CD8+ T cell exhaustion (35). Lastly, in vivo inhibition of
transforming growth factor-β (TGF-β) signaling in CD8+ T cells improved the function of
exhausted T cells (36). Despite the present evidence that certain cytokines have direct
or indirect influence on T cell exhaustion, the precise mechanism has not been defined.

7

Figure 1.2: Mechanisms of tumor immune evasion. Used with permission from
Macmillan Publishers Ltd: Nature Reviews Cancer, 12, 252-264, copyright 2012.
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B. CANCER IMMUNOTHERAPY

Immunotherapy describes several modes of treatment that aim to reorient the immune
system to fight cancer. Early on, IL-2, an inducer of T cell expansion, was the first
introduced in the treatment of cancer (37). IL-2 treatment is capable of mediating tumor
regression in tumors; however, the toxicity profile manifests in multiple organ systems
presenting as severe flu-like symptoms. Most common of these is capillary leak
syndrome, a hypovolemic state and fluid accumulation the extravascular space leading
to oliguria and ischemia. The toxicity profile of this treatment limited its clinical use.
Another form of immunotherapy called adoptive cell transfer (ACT) was recently
developed to utilize the patient’s own T cells with anti-tumor activity and expand those
cells in vitro then reinfusing into the patient (38). Once reinfused, the T cells require
binding to MHC molecules to induce their functions; however, tumor intrinsic functions
may downregulate MHC on the surface of the tumor cell. Next, Chimeric antigen
receptors (CAR) T cells were developed as engineered, patient-derived T cells with the
ability to recognize and kill tumor cells without the MHC binding requirement (39). CAR T
cells have additional co-stimulatory molecules that enhance its ability to proliferate. For
example, a patient with advanced follicular lymphoma treated with CAR T-cell therapy
targeting CD19 presented with dramatic regression after infusion (40). Finally, immune
checkpoint inhibition (ICI) is a new mode of immunotherapy that has truly revolutionized
cancer treatment and exhibits impressive responses in several tumor. The focus of my
research explored markers of the immune response that may be associated with
improved response to ICIs.

Inhibition of immune checkpoints has multiple FDA-approved indications for the
treatment of various malignancies, including melanoma, non-small cell lung cancer
9

(NSCLC), bladder cancer and many more, and has allowed clinicians another tool in
their armament of cancer treatments (41-44). This form of treatment shifts the
perspective from giving a patient medication to destroy tumor cells to giving medication
to aid their immune system in mounting a response against the tumor. The medications
include agents that target immune checkpoints such as ipilimumab (Yervoy®, BristolMyers Squibb), an antibody to CTLA-4, nivolumab (Opdivo®, Bristol-Myers Squibb), and
pembrolizumab (Keytruda®, Merck) which are antibodies to programmed cell death
protein 1 (PD-1), the receptor for PD-L1, as well as atezolizumab (Tecentriq®,
Genentech), avelumab (Bavencia®, Merck/Pfizer), and durvalumab (Imfinzi®,
AstraZeneca), antibodies to PD-L1. The checkpoints these medications target act as
mediators for the balance and escape phases of cancer immune editing, as discussed
above. By targeting these inhibitory receptors, cancer cells lose the ability to suppress
the antitumor response.

The use of ICIs in oncology has been met with excitement and hope as another pillar of
treatment that is promising and results in long and durable responses. In the treatment
of NSCLC patients, Nivolumab improved median overall survival as compared to
Docetaxel treatment (9.2 mos vs. 6.0 mos; P <0.001) (42). Dual blockade of PD-1 and
CTLA-4 in patients with melanoma has demonstrated improved tumor control with
median duration of response at 22.3 months (45, 46). In addition to the improvement of
overall survival, the treatment regimen is more tolerable as compared with docetaxel
with less grade 3/4 adverse events. Importantly, in a long-term follow-up study of 129
nivolumab-treated patients with NSCLC, the 3-year OS rate was only 18% (47). The
benefit of ICIs is the potential for long, durable responses, however, it’s been shown that
approximately 20% of the treated-population actually realizes benefit (48, 49). To
improve that response, durable biomarkers of response are essential for clinical
10

management. Herein I review the body of scientific work assessing both tumor-specific
and peripheral blood markers that are promising predictive biomarkers (Table 1).

C. TUMOR BIOMARKERS OF RESPONSE

Due to a low percentage of durable responders to ICI treatment, research efforts into
developing predictive biomarkers of response began (Table 1.1). Given the mechanism
of action of PD-1 and PD-L1 inhibitors, initial studies into biomarkers tried to determine
whether the efficacy of these monoclonal antibodies correlated with PD-L1 expression in
the tumor.
PD-L1 Expression
PD-L1 is a ligand of the PD-1 receptor, expressed on both tumor cells and APCs, and
plays an important role in the inhibition of the normal T cell-mediated immune response.
When PD-L1, expressed on the tumor cell, binds to PD-1 receptor on T cells, this leads
to exhaustion of effector T cells and poorer prognosis of the patient (50). For the agents
targeting the PD-1/PD-L1 axis, tumor expression of PD-L1 has been used as a method
of selecting appropriate patients to be treated; however, it has not proven to be universal
(51, 52). In cancers that express PD-L1, the interaction with the PD-1 receptor
expressed on T cells, B cells, and natural killer (NK) cells of an activated immune system
characterize an immune-evasive response by the tumor. Monoclonal antibodies that
then bind to PD-1 or PD-L1 prevent cancer cells’ immune evasion (53). For this reason,
expression of PD-L1 is currently utilized in the clinic as the best available biomarker to
predict response to ICI targeting this checkpoint (51, 53, 54).

Interpretation of PD-L1 expression levels has caused confusion as there are several
methodologies that utilize different cut-offs differentiating between positive and negative
11

expression. The currently utilized companion diagnostic tools were developed for use
with pembrolizumab and nivolumab, both PD-1 inhibitors. Each measurement is
completed using immunohistochemistry (IHC). However, there were two antibodies
developed specifically for each of the medications; antibody 22C3, anti-PD-L1, for
pembrolizumab and antibody 28-8, anti-PD-L1, for nivolumab. The Tumor Proportion
Score (TPS) is the percentage of PD-L1 positive tumor cells showing partial or complete
membrane staining relative to all viable tumor cells present in the sample. A positive
TPS using pembrolizumab’s companion diagnostic (antibody 22C3) is considered to be
greater than 50% whereas for nivolumab (antibody 28-8), expression cut-offs are set at
>1%, >5% or >10%. There are ongoing efforts to standardize and optimize PD-L1
expression testing that include collaboration by the current ICI manufacturers to develop
a universal PD-L1 testing platform (55).

From a simply biological perspective, measuring the expression of the membrane-bound
PD-L1 ligand should indicate tumors that will respond to therapy. However, limitations of
this diagnostic test, such as timing of tissue acquisition, tumor heterogeneity, and timing
of therapy relative to the inducible expression of PD-L1, raise the question as to whether
expression of this molecule truly represents an anti-PD-1 or anti-PD-L1 responsive
tumor (52). The Keynote-001 trial sought to correlate response to pembrolizumab with
expression of PD-L1. In the melanoma arm, PD-L1 expression correlated with increased
response rate in 49% compared with 13% of PD-L1 negative patients. The NSCLC arm
of this study showed that, when PD-L1 expression on tumor cells was greater than 50%,
response to pembrolizumab was predicted (67% PFS rate at 6 months). Of these
patients, nearly 25% demonstrated PD-L1 protein on greater than 50% of tumor cells.
For all-comers, response rate to pembrolizumab was about 19%. Importantly, median
progression free survival (PFS) was 14.1 months in PD-L1 strongly positive patients
12

compared with 9.3 months in the weakly positive population (56). Response rates
appear to be higher in tumors with elevated PD-L1 expression; however, some tumors
that do not express PD-L1 still exhibit a response to therapy (57). Given these
observations, measuring PD-L1 expression in a tumor cannot serve as an exclusionary
predictive biomarker of response. Development of robust and validated biomarkers of
response for ICI therapy has become a priority in this burgeoning field.
Tumor-Infiltrating Lymphocytes and T-cell Receptors
The abundance of tumor-infiltrating lymphocytes (TILs), specifically CD8+ T-cells
expressing PD-1 or CTLA-4, have previously been identified as indicators of successful
checkpoint inhibition (58, 59). There is a demonstrated difference, however, between
increased populations of CD8+ T cells found at the invasive tumor margin versus those
in the tumor itself with the former being the most closely associated with increased PDL1 expression. In addition, double positive PD-1+/CTLA-4+ CD8+ T cells within the
melanoma were strongly associated with improved progression-free survival (PFS) (15.9
mos vs. 9.9 mos, P=0.04) after anti-PD-1 therapy (59). Out of 15 patients in a validation
cohort assessing the predictive ability of CD8+ T cells abundance, quantified CD8+ T
cell density accurately predicted 4 out of 5 patients in the true progression group and 9
out of 9 patients in the true response group. This data supports the notion that the
abundance of TILs correlates with improved anti-PD-1 therapy response. Limitations of
this assay include the need for assessing tumor tissue sample immediately prior to
treatment. Most NSCLC patients undergo biopsies prior to resection and follow up with
chemotherapy and/or radiotherapy. However, another biopsy would be necessary prior
to addressing if the patient would be a candidate for ICI blockade. It is likely that the
genomic and immune properties of the tumor would have changed since that initial
biopsy so analyzing the original sample for TILs may not be accurate for subsequent
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therapy. Further, it is cumbersome, and sometimes unreasonable, for a patient to
undergo additional biopsies.

T-cell receptor (TCR) diversity, or the range of difference TCRs expressed, plays a vital
role in host defense (60). Diversity refers to the degree of dispersion between clonotypes
or phenotype of a clone of cells. TCR diversity is generated by mutations resulting from
recombination, random insertion, deletion and/or mismatch in the genes that encode Tcell receptors, and there is potential to create between 106 to 1020 TCR clonotypes. TCR
diversity has been examined before and after checkpoint inhibition to assess its impact
on T-cell clonal populations and its effect on response (61-63). In both peripheral blood
as well as tumor samples, a substantial increase in “diversity” of unique TCR V-beta
CDR3 sequences after anti-CTLA-4 treatment was observed and presumably led to proinflammatory or autoimmune hyper-responsiveness. Kvistborg et al monitored immune
reactivity against a panel of 145 melanoma-associated epitopes in patients receiving
anti-CTLA-4 treatment. Comparison of T cell reactivities prior to and after treatment for
40 melanoma patients demonstrated that anti-CTLA-4 treatment induces a significant
increase in the number of detectable melanoma-specific CD8 T cell responses (P
=0.0009) (63). There was an increase in the total number of unique sequences but no
one specific clone became predominant. In a study of patients with metastatic melanoma
treated with PD-1 blockade, tumors that illustrated expansion of pre-existing TCRs, a
more “focused” repertoire, were most likely to respond to therapy (58). The “focused”
repertoire, defined as a more restricted TCR beta chain population, correlated with
clinical response after pembrolizumab therapy (P=0.004). Together, these data suggest
a “diverse” profile of TCRs present in T cells infiltrating tumors is associated with
improved response with anti-CTLA-4 treatment. A “focused” TCR profile is associated
with improved response with anti-PD-1/PD-L1 blockade. Immuno-sequencing of TIL and
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TCR diversity may be effectively used as predictors of response or for monitoring drug
efficacy and toxicity.
Mutational Burden
Mutations give rise to the development of cancer; however, the degree of burden differs
between different cancer types. Among all cancers, melanoma and lung cancers exhibit
the highest mutational burden as determined by cataloging somatic mutations (64).
Patients who harbor tumors exhibiting increased somatic mutations, such as
nonsynonymous variants (a nucleotide substitution that alters the amino acid sequence),
correlated with a benefit from CTLA-4 blockade (65). In a study of 64 malignant
melanoma patients treated with anti-CTLA-4, whole-exome sequencing was conducted
on tumor and matched blood samples. Somatic mutations and candidate neoantigens, a
new antigen developed within the tumor the immune system has not previously been
exposed to, were characterized. A discovery set of 11 patients who exhibited long-term
clinical benefit and 14 patients who presented with minimal benefit were characterized. A
neoantigen signature, determined by genome-wide somatic neoepitope analysis,
predicted strong response to CTLA-4 blockade. This signature was validated in a set of
39 patients. Tobacco smoke, which contains carcinogens such as arsenic and benzene
that induce mutations, was associated with benefit of PD-1 blockade in lung cancer
patients (66). A smoking signature was determined utilizing whole-exome sequencing of
NSCLC samples in two independent cohorts, n=16 and n=18. The smoking signature,
identified as transversion high (i.e. the substitution of a purine for a pyrimidine DNA base
or vice versa) and is associated with elevated neoantigen burden, lead to improved
objective response, durable clinical benefit, and progression-free survival (66). The
observation that nonsynonymous mutation burden is associated with anti-PD-1 efficacy
is consistent with the hypothesis that APC recognition of neoantigens, formed because
of somatic mutations, is important for the activity of anti–PD-1 therapy.
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DNA repair mechanism mutations, especially in the mismatch repair (MMR) pathway,
also contributed to the mutational burden leading to improved response to certain
therapies. Patients exhibiting MMR-deficient tumors, which occurs in a small population
of cancers, benefited from anti-PD-1 treatment (67). In 41 patients with metastatic
carcinoma with or without MMR-deficient disease, anti-PD-1 treatment was
administered. The 20-week immune-related progression free survival rate showed an
improved response in patients with the MMR-deficient cancer (78% vs. 11%). Wholeexome sequencing revealed 1,782 somatic mutations per tumor in the MMR-deficient
tumors compared to 73 in the MMR-proficient tumors (P=0.007). The resulting tumors
express high levels of PD-L1 and possess a cytokine-rich microenvironment with
immune infiltrates expressing PD-1, CTLA-4 or LAG-3, signaling a primed response.
Since then, this study has been expanded to evaluate the efficacy of PD-1 blockade in
patients with advanced MMR-deficient cancers across 12 tumor types and is currently
still ongoing (68). Eighty-six patients with at least one prior therapy and evidence of
progressive disease underwent treatment with a PD-1 inhibitor. Mismatch-repair
deficiency was identified in all patients using either polymerase chain reaction or
immunohistochemistry. The study is ongoing and has yet to reach the primary endpoint
of overall survival. In May of 2017, Keytruda (pembrolizumab) received an indication for
the treatment of adult and pediatric patients with unresectable or metastatic solid tumors
that have a microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR)
hypermutated malignancy (69). These works have collectively led to the fast-tracked
approval for the first cancer treatment for any solid tumor with a specific genetic feature.
Inflammatory Gene Signatures
Other factors inherent to the nature of the tumor microenvironment may determine
resistance or susceptibility to immunotherapy. Gamma interferon-inducible genes have
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been highlighted in the literature in defining a “hot” tumor – or a tumor with an interferon
responsive signature (70, 71). Class II MHC-positive melanomas that have this
interferon responsive signature respond to PD-1 blockade. Other studies show the loss
of this signature reduces efficacy of treatment (72). First, whole exome sequencing of
tumors from 16 patients with melanoma who did not respond to ipilimumab therapy and
had reduced overall survival, identified multiple-copy-number alterations resulting in the
loss of interferon gamma pathway genes, including IFNGR1 (73). Next, patients from the
KEYNOTE-012 (NCT01848834) study that assessed the use of pembrolizumab for the
second-line treatment of head and neck squamous cell carcinoma (HNSCC) were tested
using 4 multi-gene expression signatures (74). These 4 gene sets included “IFN-γ” (6gene), “TCR signaling” (13-gene), “expanded-immune” (18-gene) and “de novo” (33gene). The “IFN-γ” set included CXCL9, CXCL10, IDO1, IFN- γ, HLA-DRA, and STAT1.
All 4 sets showed strong association with PFS (P<0.0005) with “IFN-γ” the top performer
with a positive predictive value (PPV) for response of 40.0%, and negative predictive
value (NPV) of 95.0%. In a third study, patients treated with atezolizumab, a PD-L1
inhibitor, demonstrated an increased response when an INF-γ gene signature was highly
expressed (75). In this open-label phase 2 trial, 286 patients with NSCLC previously
treated with platinum chemotherapy were to be randomized to receive atezolizumab or
docetaxel therapy. Overall survival for the atezolizumab group was 12.6 months (95% CI
9.7-16.4) versus 9.7 months (95% CI 8.6-12.0) for the docetaxel group. More
impressively, in an additional exploratory analysis, patients treated with atezolizumab
with high T-effector-interferon-γ-associated gene expression (Teff High) improved overall
survival (HR 0.43; 95% CI 0.24–0.77), the best improvement in response. End of the
study was reached before overall survival could be assessed. Teff high was associated
with a median follow-up of 15 months where Teff low had a median follow-up of 10
months (75). Another study assessed the regulation of a library of 209 different cytokines
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from the human cytokine library, IFN-γ stood out due to its autocrine mechanism to
elevate STAT1 and induce internalization of gp130, a component of many heterodimeric
cytokine receptors (76).

These studies have identified the impact of inflammatory genes and pro-inflammatory
cytokines on immune response. IFN-γ may be critical in this process due to its
hypothesized role as a master checkpoint regulator for many other cytokines. STAT
family proteins generally reside in the cytoplasm as inactive homodimers (77). Receptorassociated JAKs become activated upon ligand binding leading to phosphorylation of
specific receptor tyrosine residues. These residues direct SH2-dependent recruitment of
specific STATs which as then activated and released and reorient into antiparallel
dimers where the SH2 domain on one STAT binds to the phosphotyrosine on the other
STAT. Activated STAT dimers translocate into the nucleus. In response to IFN-γ, STAT3
protein phosphorylation is reduced in favor of increasing both expression and
phosphorylation of STAT1. Once phosphorylated, STAT1 proteins form homo- or
heterodimers and translocate to the nucleus where they act as transcription activators.
This simple elevation of STAT1 and down-regulation of STAT3 by IFN-γ interferes with
multiple cytokines using STATs as key signal transducers.
Gut Microbiome
Several studies have shown that the intestinal microbiome may modulate the anticancer
effect of certain chemotherapies, such as cyclophosphamide (78-80).
Cyclophosphamide alters the composition of the gut microbiota, specifically translocating
select Gram positive bacteria into secondary lymphoid organs leading to generation of T
helper 17 (Th17) cells and memory Th1 immune responses. The specific Gram-positive
bacteria identified were Lactobacillus johnsonii, Lactobacillus murinus and Enterococcus
hirae. When assessing the therapeutic efficacy of anti-PD-1 treatment alone or in
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combination with anti-CTLA-4 treatment in mice with sarcoma or melanoma, mice were
raised in specific pathogen-free conditions and then either treated for 14 days with
broad-spectrum antibiotics (ampicillin, colistin, streptomycin) or left untreated (81). Mice
that were exposed to antibiotics exhibited a worse prognosis when treated with an ICI.
The researchers also examined the impact of antibiotics on 249 human patients with
NSCLC, renal cell carcinoma (RCC) or urothelial carcinoma treated with ICI. Patients
exposed to antibiotics two months prior to ICI treatment or one month after exhibited
decreased PFS (3.5 mos vs. 4.1 mos, P=0.017) and decreased overall survival (11.5
mos vs. 20.6 mos, P<0.001) as compared to patients with no exposure to antibiotics.
Analysis of the composition of the gut microbiota implicated A. muciniphila with favorable
clinical outcome (P=0.004). In a separate prospective study, microbiome samples were
collected from patients with metastatic melanoma patients prior to treatment with antiPD-1 therapy (82). Thirty-five patients were classified as non-responders and fifty-four
classified as responders based on Response Evaluation Criteria in Solid Tumors
(RECIST) criteria at 6 months after treatment initiation. Diversity of the gut microbiome
was significantly higher in the responder group compared to the non-responders
(P<0.001). R. faecalibacterium was abundant in the responder group while Bacteroides
thetaiotaomicron was found present in non-responders. R. faecalibacterium in the gut
was associated with higher levels of effector CD4+ and CD8+ T cells in the systemic
circulation with a preserved cytokine response to anti-PD-1 therapy, whereas patients
with a higher abundance of Bacteroides in the gut microbiome had higher levels of
regulatory T cells (Treg) and myeloid derived suppressor cells (MDSC) in the systemic
circulation, with a blunted cytokine response. The proposed mechanism by which the gut
microbiome enhances systemic and anti-tumor immune responses suggests that
increased antigen presentation improves effector T cell function in the periphery and the
tumor microenvironment. Specific bacteria, such as E. hirae and A. microsciphilia, are
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also associated with obesity and diabetes. Previous microbiome-wide association
studies not only linked cancer to the gut microflora but also to obesity, cardiovascular
disease, and type 2 diabetes (83). These data prompt the question as to whether the
inflammatory states induced by these chronic conditions give rise to the microbiome that
impacts ICI treatment.

D. BIOMARKERS OF RESPONSE IN PERIPHERAL BLOOD

In the clinical setting, the ease of access to a patient sample with which to measure a
potential biomarker is weighed heavily in addition to its precision of use. Currently, only a
tumor-derived biomarker of response has been approved by the FDA for anticipating
response to ICI. PD-L1 expression is typically assessed from a biopsy of the solid tumor
and, as discussed earlier, the timing of tissue acquisition, tumor heterogeneity, and
timing of therapy affect the PD-L1 expression value. PD-L1 expression is a dynamic
parameter that cannot be adequately represented with a single snapshot (84). Liquid
biopsies, in addition to being repeatable and easily accessible, allow for characterization
of the dynamic changes of the tumor. Circulating tumor cells (CTCs) sampled from the
primary tumor site likely share the immune escape mechanisms (85). In addition to PDL1 expression, peripheral blood may allow for identification of other immune factors
influencing the response to ICIs. Identification of a robust biomarker that is more readily
available from peripheral blood would, not only avoid the need for additional biopsies,
but could then be streamlined in the clinic to allow for more efficient treatment.
Peripheral Immune Populations
Tumor immune cell subtypes have been assessed within the tumor microenvironment,
and specific cells are associated with improved response to ICIs (58, 59). These are
typically measured from a tumor biopsy of the primary or metastatic tumor site. However,
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these sites are often not very accessible and so immune cell subpopulations in the
periphery can be explored using multi-parametric flow cytometry (86, 87). In a study of
209 advanced melanoma patients treated with ipilimumab, baseline frequencies of
myeloid-derived suppressor cells (MDSC), regulatory T cells (Treg), serum lactate
dehydrogenase (LDH), eosinophil count, and other clinical characteristics were
measured then analyzed by Cox regression analysis to identify factors associated with
improved overall survival (88). The study, conducted in two phases, aimed to first
identify biomarker candidates that best fit a prognostic model and in the second phase
validate the biomarker combination. Of 28 potential variables measured, a six
biomarkers signature was confirmed to predict improved survival (low LDH count,
elevated eosinophils, low absolute monocytes, high absolute lymphocytes, low
Lin−CD14+HLA-DR-/low MDSC frequencies, and elevated CD4+CD25+FoxP3+ Treg
frequencies). The immunological rejection of cancer is dependent on the balance of
interactions between T cells and regulatory cells (89). Eosinophils, lymphocytes,
monocytes, Tregs and MDSCs are components involved in this regulatory network.
Eosinophils are multifunctional white blood cells with cytosolic, large granules containing
a variety of cytokines and chemokines. These cells play a part in tumor surveillance and
tumor rejection. MDSCs and Tregs suppress the functions of T cells potentially
counteracting the benefit of ICIs.

Another study investigating peripheral markers of response suggests that CD4+ T cells
expressing PD-1 in peripheral blood are associated with poor clinical outcomes for
NSCLC patients treated with a PD-1 inhibitor (90). Peripheral blood mononuclear cells
(PBMC) retrieved from 42 NSCLC patients at diagnosis and from an additional 25
healthy donors were assessed for frequency of PD-1 expression on both CD4+ and
CD8+ T cells. PD-1+ CD4+ T cells were elevated among NSCLC patients as compared
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to healthy donors (13.3% vs. 8.8%, p=0.0045). However, there was no difference in PD1 expression on CD8+ T cells among both populations. CD4+ T cell subgroups defined
as high-PD-1 (PD-1 > 12.27%) and low PD-1 (PD-1 <12.27%) were based on the mean
expression levels of the 42 NSCLC patients. Lower rates of both OS and PFS were
associated with the high-PD-1 groups as compared to the low-PD-1 group (median OS:
397 days vs. 721 days, p=0.028; median PFS: 88 days vs. 391 days, p=0.044). In
addition, the elevated PD-1 expression on either T cell subset isolated from peripheral
blood was not associated with PD-L1 expression on tumor tissue. These results suggest
a biomarker of response to checkpoint inhibition could be established based on cell
surface markers of immune cell subsets in peripheral blood.
Peripheral Immunoscore
As discussed earlier, it has been reported that patients with high baseline TILs are
associated with improved response to ICI therapy. Immunoscores are a signature of
immune cell populations that indicate disease responsive to ICI treatment. Single
parameters, like tumoral PD-L1 expression, are limited in their prognostic value, but the
combination and interaction of several parameters may establish a robust predictor of
response. Tumor immunoscore analyses have been primarily conducted on biopsies of
primary or metastatic tumor lesions, but there may be promise in completing the same
analyses of immune cell subsets in the periphery (91, 92). Further, others have
hypothesized that immune cells in peripheral blood may be different among patients with
metastatic disease leading to a different response to immunotherapy. Single marker
studies have assessed the prevalence of circulating CCR7+ CD8+ T lymphocytes in
head and neck cancers, or MDSC in advanced melanoma in relation to PFS (93, 94).
However, a multivariate panel that measures immune cell subsets is more likely to be an
efficient prognostic assay than any single immune effector cell (95). In a study by
Farsaci et al, peripheral immunoscores were established from analysis of PBMC prior to
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treatment with immunotherapy to define whether there was a correlation of what with
efficacy of immune-based treatment (87). PBMC analyzed were collected from two
sources: patients with metastatic cancer randomized to receive docetaxel with or without
PANVAC vaccine or prostate cancer patients with metastatic bone lesions randomized
to receive radionuclide with or without PROSTVAC vaccine (96, 97). PANVAC is a
poxviral-based vaccine therapy targeting carcinoembryonic antigen (CEA) and mucin-1
in carcinoma. PROSTVAC is prostate specific antigen (PSA)-targeted immunotherapy. A
peripheral immunoscore accounting for "classic" immune cell types (CD4, CD8, NK cells,
regulatory T cells, and MDSCs) revealed no differences in progression-free survival
(PFS) for either arm in both trials. Importantly, an immunoscore developed from a
“refined” subsets of immune cells with a phenotype reflecting immune function revealed
statistically significant differences in PFS. Peripheral immunoscores have yet to be
assessed at baseline of PD-1 or PD-L1 inhibitor treatment, and so different immune cell
properties may be better predictive of interactions in the PD-1/PD-L1 pathway. The
clinical application of this assay is promising, but further validation in all ICI pathways is
required.
Tumor-derived Exosomes
Tumor cells produce more extracellular vesicles than normal cells, which may explain
why plasma exosomes are substantially higher in patients with cancer than in normal
donors (98). Tumor-derived exosomes, or “TEX”, carry molecular cargo from the tumor
microenvironment and can also deliver suppressive or stimulatory signals to immune
cells. TEX are typically isolated from supernatants of cultured human or murine tumor
cell lines using ultracentrifugation or sucrose density gradient centrifugation; however,
this method is time-consuming and is not reproducible in a scaled-up environment for
exosome recovery from numerous human specimens. Taylor, et al. developed a size
exclusion chromatography (SEC) approach to readily recover intact TEX from small
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volumes of plasma (99). TEX do mirror some of the key molecules characteristic of the
parent tumor cell and thus may serve as a surrogate of the tumor microenvironment
(100). As such, they carry tumor-associated antigens, major histocompatibility complex
(MHC) class I and II molecules, and a variety of cytokines that enable TEX to stimulate
or suppress immune cells. However, in another study, antibody-based therapies such as
ICIs can be less effective because TEX carry the antigen targets of ICI and can act as a
sponge to “soak” up the antibodies. Therefore, diminishing concentrations of drug are
measured at the tumor site (101). TEX may be used as a predictive model for treatment
due to it serving as a surrogate for the tumor microenvironment; however, further
validation is required.
Angiopoietin-2
Angiogenesis, the formation of new vasculature, is a hallmark of cancer. Angiogenic
factors, such as angiopoietin-2 (ANGPT2), play significant roles in the inhibition of
immune activities by inhibiting dendritic cell maturation, tumor infiltration by lymphocytes,
promoting Tregs and MDSC expansion (102-104). Increased expression of Tregs and
MDSCs directly suppresses the immune response. ANGPT2 is upregulated in tumor
vasculature and confers resistance to anti-angiogenesis therapy targeting vascular
endothelial growth factor (VEGF) (105). Although ANGPT2 had been previously
identified as a prognostic marker of outcome. For certain cancers being treated with antiVEGF therapy, it may have the potential to be used as a predictive biomarker for
immune checkpoint inhibition. In metastatic melanoma patients, both high pretreatment
concentrations and increases in serum ANGPT2 during treatment were associated with
reduced overall survival in CTLA-4 and PD-1 blockade–treated patients (106). Further
data indicates that the features of tumor blood vessels can limit the anti-tumoral
functions of T cells, specifically cytotoxic CD8+ T cells. Dual blockade of VEGF and
ANGPT2 as a tumor-conditioning strategy has been shown to increase the efficacy of
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anti-PD-1/PD-L1 therapy in cancer (107). In both transgenic and transplant mouse tumor
models, dual blockade delayed tumor progression and was found to expand tumorassociated-macrophages (TAMs) and dendritic cells. In addition, the proportion of CD8+
TILs were increased. When PD-1 blockage was introduced into the mouse model, the
anti-tumoral activity of the dual blockade was further enhanced. The harmonizing actions
of the antiangiogenic therapy with immune checkpoint inhibition may allow for synergistic
efficacy in treatment. ANGPT2 addresses a lot of the criteria of a robust peripheral
biomarker of response. It is easily sampled, validated in multiple tumor types in different
combinations of ICIs, and is continually monitored during treatment. A comparison study
of ANGPT2 levels and PD-L1 expression is needed to determine which one is a more
robust biomarker.

E. RESEARCH PROPOSAL OVERVIEW

The identification of potent immune response inhibitory pathways, regulated by
interactions managed by PD-1 and CTLA-4, have paved the way for revolutionizing
immunotherapy for cancer treatment. Despite the development of immunotherapies
utilized in the clinical setting today, we still understand little of the molecular mechanisms
that initiate or subdue T cell exhaustion. With the increasing use of these agents in the
clinic as well as many other ICIs currently in the pipeline, the demand for a validated and
robust biomarker of response is high. Due to the potential for long durable responses, a
validated and robust biomarker of response is needed to increase the rate of long-term
responders from merely 20%. Further analyses of peripheral immune cells, cytokine
production and the mechanisms influencing T cell exhaustion will be critical to defining a
peripheral blood biomarker that is accessible, reproducible and validated.
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I sought to identify a biomarker of response to ICIs that improves patient care using a
combination of healthcare outcomes and molecular markers that correlate to therapeutic
efficacy. Two testable research hypotheses were developed: First, I proposed that
chronic inflammatory pretreatment comorbidities would impact baseline immune
system function and regulation of response to cancer. This includes
hyperlipidemia, hypertension, diabetes mellitus and obesity; collectively known as
metabolic syndrome (MetS) as well as chronic obstructive pulmonary disorder
(COPD). The comorbid history of MetS and/or COPD among NSCLC patients
correlates with response to immune checkpoint inhibitor treatment. This
hypothesis was assessed in both a retrospective single-center study as well as a
national health outcomes observational study. Secondly, MetS and COPD
comorbidities will provide additional understanding of the underlying biology of
immune cell subsets and cytokine profiles in the periphery that influence
response to ICIs.

The work herein documents the use of translational research and
pharmacoepidemiology utilized to improve the clinical use of ICIs in cancer through
improving patient selection via a more robust biomarker of response.
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Table 1.1: Overview of candidate biomarkers of response for immune checkpoint inhibitors.

TYPE
Tumorderived

BIOMARKER
TumorInfiltrating
Lymphocytes
(TILs)

T-Cell Receptor
(TCR) Diversity
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Mutational
Burden

DISEASE
SETTING

TREATMENT

CUTOFF/MEASURE

Melanoma/
NSCLC

Anti-PD-1

20%

Melanoma

Anti-CTLA-4

"Diverse"

Melanoma

Anti-PD-1

"Focused"

Melanoma

Anti-CTLA-4

> 100 mutations

NSCLC

Anti-PD-1

CLINICAL SIGNIFICANCE
PD-1+/CTLA-4+ CD8+ T Cells
>20% were associated with
improved PFS (15.9 Mo vs. 9.9
Mos, P=0.04).20
Pre- and posttreatment T cell
reactivity after anti-CTLA-4
treatment show significant
increases in number of detectable
melanoma-specific CD8+ T cell
responses (P=0.0009).21,22
A more restricted TCR beta chain
usage (less diverse and more
clonal) correlated with clinical
response after pembrolizumab
therapy (P=0.004).19
Patients with long-term clinical
benefit (PFS > 6 months), had
increased mutational burden
(P=0.04).25
Greater PFS in those with higher
nonsynonymous mutation burden
compared to those with lower
nonsynonymous mutation burden
(HR 0.19, 95% CI 0.08–0.47, P =
0.0004).26

Multiple

Anti-PD-1

MMR-deficient

IFN-γ Gene
Signature

Melanoma

Anti-CTLA-4

High expression of
IFN-γ gene
signature

NSCLC

Anti-PD-L1

High expression of
IFN-γ gene
signature

Gut Microbiome

mRCC/NS
CLC

Anti-PD-1

E. hirae & A.
microsciphilia

Immune Cell
Populations

NSCLC

Anti-PD-1

PD-1 >12.27% on
CD4+ T Cells
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Mismatch
Repair (MMR)

Peripheral
Blood

Response rate and PFS for MMRdeficient colorectal cancers were
40% and 78% compared to 0% and
11% for MMR-proficient colorectal
cancers, respectively.27 Current
study expanded for 12 more tumor
types and is ongoing.28
Strong associated with improved
PFS (P=0.0005). PPV of 40.0%,
NPV 95.0%.33
NSCLC patients treated with
atezolizumab with high T-effectorIFN-γ-associated gene expression
(Teff IFN-γ High) improved overall
survival (HR 0.43; 95% CI 0.24–
0.77), compared to Teff IFN-γ Low
(HR 1.10, 95% CI 0.68-1.76).34
Presence of certain gut flora has
been associated with improved
efficacy of nivolumab. In addition,
antibiotic therapy 2 months or or
month after nivolumab-treatment,
resulted in reduced PFS (2.3 Mos
vs. 9.1 Mos, P<0.001).39
Lower rates of both OS and PFS
were associated with the high-PD-1
groups as compared to the low-PD1 group (median OS: 397 days vs.
721 days, P=0.028; median PFS:
88 days vs. 391 days, P=0.044).45

Peripheral
Immunoscore

Breast

Immunotherap
y Vaccines

Tumor-derived
Exosomes
(TEX)

Multiple

N/A

Angiopoietin-2
(ANGPT2)

Melanoma

Anti-CTLA-4/
Anti-PD-1

Score based on %
CD4, % CD8, %
Treg, %MDSC,
%NK, Ratio
CD4:Treg, Ratio
CD8:Treg, Ratio
CD4:MDSC, Ratio
CD8:MDSC

ANGPT2 < 3,175
pg/mL
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Peripheral immunoscore of refined
subsets of immune cells revealed
statistically significant differences
in PFS (P < 0.001) for breast
cancer patients receiving docetaxel
plus immunotherapy vaccine and in
prostate cancer patients receiving
radionuclide plus immunotherapy
vaccine (P = 0.004).43
TEX can act as a snapshot of the
tumor microenvironment but easily
assessed in peripheral blood.55
Patients with low pretreatment
ANGPT2 experienced improved
survival as compared to those with
low ANGPT2 concentrations (7.9
Mos vs. 34.6 Mos, P<0.0001).61
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CHAPTER 2
A. OVERVIEW

The utilization of pharmacoepidemiological techniques was a familiar task to myself and
to our laboratory. To assess the ability of measuring survival and response from
exposure to a certain treatment, we evaluated the role of statins in the cancer
population. Our laboratory has prior experience in the analysis national healthcare
claims datasets, such as Truven Marketscan (108). The role of HMG-CoA reductase
inhibitors (statins) in chemoprevention and cancer treatment has been deliberated in the
literature (109-113) as well as the mechanism by which they may exert their effect and
improve overall survival (OS) in cancer patients (114-117). Recent cohort studies have
shown that current statin use is associated with significantly lower risk of cancer death
(111) while other studies have shown that statin use following diagnosis can reduce
cancer-specific mortality in breast (118), colon (119, 120), and lung cancer (121)
patients. However, some skepticism remains as mitigation of all confounding factors is
not possible with cohort or pharmacoepidemiological studies (122, 123). Prospective
evaluation of statins as monotherapy in cancer has been attempted, but a recent review
of clinical trials of statin monotherapy in cancer revealed little effect (124). In contrast,
prospective trials using a combination of statin with chemotherapy have shown improved
survival in cancer patients (125-129). Given the relative safety profile of statins, rational
combination therapies may provide cancer patients clinical benefit at the expense of
minimal toxicity risk.

Mechanistically, statins inhibit 3-hydroxy-3-methylglutarylcoenzyme A (HMGCoA)
reductase, the rate-limiting enzyme of the mevalonate pathway, which ultimately
31

ADAPTED FROM: El-Refai et al, JCO Clinical Cancer Informatics (2017)
DOI:10.1200/CCI.17.99919
produces cholesterol along with isoprenoids; intermediate pathway metabolites such as
farnesyl pyrophosphate (FPP) and geranyl geranyl pyrophosphate (GGPP) (130, 131).
The physiological importance of isoprenoids in normal and cancer cells is critical for
facilitating membrane anchoring of numerous signaling molecules including G-proteins
such as Ras and Rho (132). Furthermore, constitutive activation of signaling pathways in
cancer is dependent on cholesterol availability for formation of lipid rafts (133, 134).
Recognition of the biological importance of FPP and GGPP led to drug development
efforts of isoprenylation enzyme inhibitors (135, 136), which ultimately stalled in early
phase studies due to toxicity and lack of efficacy. Pharmacologically, bisphosphonates
also act as isoprenylation inhibitors (137, 138) and are widely used to inhibit bone
resorption and treat osteoporosis. Bisphosphonates have also been used extensively to
treat cancer patients with bone metastases (139-142). Their effect on reducing bone
metastasis is significant and is consistent with the observations that they cause
apoptosis in tumor cells via inhibition of the mevalonate pathway as well as tumor cell
invasion in vitro (143, 144). Reduced cholesterol levels trigger a negative feedback
loop, which ultimately leads to the upregulation of mevalonate pathway genes via the
transcriptional activity of SREBP transcription factors (145, 146). Based on this
understanding, preclinical studies have demonstrated synergy when combining statins
with bisphosphonates (114, 143, 147-151) and most recently dipyridamole, which has
been shown to inhibit SREBP2 (152, 153). Thus, the use of combination therapies that
can amplify the effect of statins or abrogate the development of statin related resistance
may lead to synergistic clinical combinations. Here we used a large dataset of health
claims to test the hypothesis that statins alone, or in combination with potentially
synergistic therapies prolong survival in cancer patients. The combination of
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epidemiological evidence and preclinical data may provide strong rational for future
prospective clinical studies.

B. METHODS

We used the Truven Health MarketScan Commercial Claims and Medicare Supplemental
Databases. The Marketscan database includes approximately 40 million individuals from
over 160 large employers and health plans across the US and includes healthcare
claims with diagnosis and procedure codes for medical encounters and all prescription
medication fills. Data are de-identified in compliance with the Health Insurance
Portability and Accountability Act regulations (HIPAA) and the University of Kentucky
Institutional Review Board approved the use of the database for this study.
Patient Selection
Adults aged 18 years and older diagnosed with cancer between January 1, 2010 and
November 31, 2013 were identified using ICD-9 codes in the primary or secondary
positions. Patients with prostate and breast cancer were excluded due to the use of
hormonal therapy affecting risk for thromboembolism. Patients were diagnosed with one
of the following types of cancer: Stomach (ICD-9 codes: 151.xx), Pancreatic (157.xx),
Brain (191.xx), Lung (162.2 – 162.9), Renal (189.0, 189.1), Lymphoma (200.xx –
202.xx), Leukemia (204.xx – 208.xx), Myeloma (203.0x), Colorectal (153.xx, 154.xx), or
Gynecological (179.xx, 180.xx, 182.xx, 183.xx). At least 2 inpatient or outpatient
diagnoses within 14 days were required, and the date of the first qualifying diagnosis of
cancer was defined as the index date. Patients were required to have at least 12 months
of pre-index and a minimum of one-month post-index continuous enrollment in the
database.
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Exposure groups were defined as: statin users with no history of non-statin cholesterollowering medication use; non-statin cholesterol-lowering medication users with no
history of statin use (“non-statin users,” active control group); and those with no history
of statin or non-statin medication use (“non-users,” control group). Medication use was
based on having at least 90 cumulative days supplied in the 6 months prior to diagnosis.
Specific statins include lovastatin, pravastatin, simvastatin, rosuvastatin, atorvastatin,
fluvastatin and pitavastatin. Non-statins include fibric acid derivatives, bile acid
sequestrants, and nicotinic acid.
Measures
Patient demographic characteristics included age, gender, geographic region and urban
residence. Clinical characteristics measured during the 12-month pre-index period
included the Charlson Comorbidity Index (CCI) and Elixhauser comorbidities (Elix) (154,
155). These include 17 and 31 categories of comorbid conditions, respectively, and are
widely used for risk adjustment with health outcomes data. Additional medications
accounted for in the pre-index period included anticoagulants, antihypertensives,
antiplatelet, antiarrhythmics, and digoxin. Presence of metastatic disease was assessed
on the index date.
Statistical Methods
Pairwise analyses were done between: statins vs. non-statins, statins vs. non-users, and
non-statins vs. non-users. Propensity score matching was conducted using baseline
comorbidities, medications, and demographic information to achieve balance between
treatment groups. Propensity scoring mimics the randomization process of a clinical trial
so that each matched pair has the same baseline probability to receive either treatment
(156-158). Matched pairs should be similar in all baseline characteristics. Patients with
the same cancer type were matched using a greedy, nearest neighbor algorithm with a
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caliper set at 0.2 times the standard deviation of the propensity scores in the sample,
allowing for up to five matches for each treated person (159). Standardized differences
were calculated and shown in Appendix A. A standardized difference of <0.10 is
generally considered to be non-significant (160). To address any residual confounding
after propensity score matching, covariates were also incorporated in the final regression
models (157). The final model included the following adjustment covariates: age, CCI
score, region, anticoagulants, antihypertensives, antiplatelets, antiarrhythmics, digoxin,
elixhauser index comorbidities and pre-index history of CHD, DVT, PE, atrial thrombosis
and MI. Two sample t-test and chi-square tests were conducted to assess significant
differences between treatment groups before and after matching.

The study cohort was followed until subjects died, were lost to follow-up due to loss of
enrollment in the dataset, or the end of the study data. Cox proportional hazard
regression models, accounting for correlation within matched pairs, were used to assess
risk of death within one year of diagnosis among all cancers and then stratified among
each cancer. Follow-up was terminated for those surviving beyond one year and were
censored. Hazard ratios (HR) and 95% confidence intervals (CI) are reported. A p-value
of <0.05 is considered statistically significant. All matching and statistical analyses were
conducted in SAS.
Subgroup Analyses
A sensitivity analysis assessing the influence of age as an effect modifier was
completed. Comparisons were made within age groups of less than 65 years old, 65-75
and greater than 75 as these groups may have different treatment patterns, responses
and baseline survival prior to cancer diagnosis. The effect of dose intensity was
evaluated by limiting the statin cohort to moderate or high dosage statins and comparing
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again with non-statins and non-users (161). Patients remaining on statin therapy after
cancer diagnosis were assessed by observing the proportion of days where medication
was on-hand in the post-index period until end of follow-up. Statins were compared
individually and by type to ascertain differences among outcomes. Natural statins
include lovastatin, pravastatin and simvastatin and synthetic statins include rosuvastatin,
atorvastatin, fluvastatin and pitavastatin (162). Patients using bisphosphonates or
dipyridamole, alone or in combination with statins, were compared to non-users to
assess effectiveness or synergy in terms of survival. Bisphosphonates assessed in the
analysis were alendronate sodium, etidronate disodium, ibandronate sodium,
pamidronate disodium, risedronate sodium and zoledronic acid. Bisphosphonates and
dipyridamole were subject to the same requirement of having at least a 90 cumulative
days supplied in the 6 months prior to cancer diagnosis. For all subgroup analyses, all
cohorts were rematched via propensity score methods described above.

C. RESULTS

Table 2.1 displays the baseline demographic and clinical characteristics of the study
population by treatment group. Due to the enrollment criteria, there were no missing
values on covariates used for propensity-score matching or survival analyses. Eligibility
criteria were met by 312,907 cancer patients. Three treatment groups were established
as outlined in the CONSORT diagram (Figure 2.1): statin-users (n=65,440), non-statinusers who received non-statin cholesterol lowering medications (n=9,289) and non-users
(n=226,007). There were 8,198 patients who passed away within one year of diagnosis,
1,702 from the statin-users cohort, 216 among the non-statins users and 6,280 from the
no treatment cohort. The cohort contributed an average follow-up time of 359 days (SD
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39.3) with no differences between cancer types or treatment groups. The mean
(standard deviation, SD) age of patients in the statins, non-statins and non-users cohorts
was 74.2 (7.8), 71.8 (9.3) and 60.8 (14.1), respectively. In all treatment groups, lung,
lymphomas, and colorectal cancers accounted for the top three diagnosed cancers
whereas stomach, pancreatic, and brain cancers were the least diagnosed.
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Table 2.1: Baseline demographic and clinical characteristics of all cohorts included in
the analysis.

Statins
N=65,440
Mean
Std. Dev

Treatment Group
Non-Statins
N=9,289
Mean
Std. Dev

Non-Users
N=226,007
Mean
Std. Dev

Age

74.72

7.84

71.79

9.33

60.8

14.08

CCI

5.1

3

5.09

3

4.34

2.9

N

%

N

%

N

%

Gender (Male)
Urban
CHF

31,006
55,634
10,456

47.4%
85.0%
16.0%

4,046
7,758
1,255

43.6%
83.5%
13.5%

129,670
188,958
16,016

57.4%
83.6%
7.1%

Arrhythmias
Valvular disease
Pulmonary
Circulation
Peripheral
Vascular
Hypertension
uncomplicated
Hypertension
complicated
Paralysis

18,941
10,749
3,008

28.9%
16.4%
4.6%

2,364
1,364
414

25.4%
14.7%
4.5%

37,160
19,602
7,496

16.4%
8.7%
3.3%

20,169

30.8%

2,570

27.7%

33,064

14.6%

46,024

70.3%

6,476

69.7%

108,426

48.0%

7,300

11.2%

1,026

11.0%

12,416

5.5%

712

1.1%

86

0.9%

2,316

1.0%

Other
neurological
Chronic
pulmonary
Diabetes
(Uncomplicated)
Diabetes
(Complicated)
Hypothyroidism
Renal failure
Liver disease
Peptic ulcer
disease
HIV/AIDS
Metastatic
Cancer

5,282

8.1%

666

7.2%

16,383

7.2%

19,996

30.6%

2,599

28.0%

50,536

22.4%

21,848

33.4%

3,625

39.0%

41,544

18.4%

7,598

11.6%

1,230

13.2%

10,859

4.8%

9,122
8,605
5,558
1,278

13.9%
13.1%
8.5%
2.0%

1,378
1,433
943
184

14.8%
15.4%
10.2%
2.0%

31,244
14,718
25,865
3,776

13.8%
6.5%
11.4%
1.7%

49
9,925

0.1%
15.2%

25
1,362

0.3%
14.7%

1,035
40,686

0.5%
18.0%

Characteristic
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Rheumatoid
Arthritis
Coagulopathy
Obesity
Weight Loss
Fluids and
Electrolytes
Blood Loss
Anemia
Deficiency
Anemia
Alcohol Abuse
Drug Abuse

3,231

4.9%

497

5.4%

11,365

5.0%

3,775
3,486
4,981
9,179

5.8%
5.3%
7.6%
14.0%

527
676
656
1,228

5.7%
7.3%
7.1%
13.2%

13,017
16,740
16,717
30,267

5.8%
7.4%
7.4%
13.4%

4,005

6.1%

493

5.3%

10,277

4.5%

5,272

8.1%

767

8.3%

15,505

6.9%

522
349

0.8%
0.5%

71
51

0.8%
0.5%

3,212
2,211

1.4%
1.0%

1,252
1.9%
163
1.8%
3,705
1.6%
Psychoses
5,120
7.8%
751
8.1%
26,685
11.8%
Depression
24,187
37.0%
3,252
35.0%
26,015
11.5%
CHD
3,204
4.9%
442
4.8%
10,856
4.8%
DVT
1,346
2.1%
208
2.2%
4,481
2.0%
PE
655
1.0%
92
1.0%
1,297
0.6%
AT
4,696
7.2%
569
6.1%
5,335
2.4%
MI
1,861
2.8%
245
2.6%
6,024
2.7%
Stomach CA
3,011
4.6%
466
5.0%
9,770
4.3%
Pancreas CA
1,720
2.6%
272
2.9%
11,212
5.0%
Brain CA
15,812
24.2%
2,047
22.0%
36,891
16.3%
Lung CA
6,308
9.6%
981
10.6%
19,799
8.8%
Kidney CA
9,926
15.2%
1,507
16.2%
40,114
17.7%
Lymphomas
6,058
9.3%
948
10.2%
20,518
9.1%
Leukemia
3,031
4.6%
476
5.1%
10,367
4.6%
Myeloma
13,126
20.1%
1,817
19.6%
45,390
20.1%
Colorectal CA
5,755
8.8%
752
8.1%
34,106
15.1%
Gynecologic CA
CCI Charlson Comorbidity Index; CHF Congestive Heart Failure; CHD Coronary Heart
Disease; DVT Deep vein Thrombosis; CA Cancer
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Figure 2.1: CONSORT flow diagram. Flow diagram of the inclusion of patients from the
national healthcare claims dataset.

Screened
N~40million

Cancer Patients
N = 312,907

Non-users
n = 226,007

Statin-users
n = 65,440

Non-statin-users
n = 9,289

Bisphosphonates
n = 4,528

Bisphosphonates
n = 4,090

Dipyridamole
n = 372

Dipyridamole
n = 651
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The number of matched pairs post-propensity score matching were 39,989, 101,401 and
27,319 for the statins- vs. non-statins-users comparison, statins vs. no treatment
comparison and the non-statins vs. no treatment comparison, respectively. While
baseline differences existed among treatment groups, matching provided samples that
had minimal differences as all standardized scores were below 0.1

Figure 2.2 displays the HR and associated 95% CI for the effect of treatment group on
survival within the propensity-matched sample. Overall, there were no differences in
survival between statin-users and non-statin-users. Among all cancers, statin-use prior
to diagnosis improved overall survival compared to no treatment (HR 0.85, 95% CI 0.800.91). When stratified by cancer type, this observation held true for lung cancer (HR
0.88, 95% CI 0.78-0.98), renal cancer (HR 0.63, 95% CI 0.44-0.90) and leukemia (HR
0.73, 0.58-0.92). Non-statin-use provided a similar reduction in overall survival
compared to no treatment (HR 0.73, 95% CI 0.62-0.85); but when stratified, this held
true only for pancreatic cancer (HR 0.53, 95% CI 0.29-0.98) and leukemia (HR 0.53,
0.30-0.94).

Dose intensity analysis determined that the effect observed is not dosage-dependent
(Figure 2.3). By removing low-dosage statins and comparing to non-statins and nonusers, overall survival was of the same magnitude and direction observed in the overall
analysis. The sensitivity analysis assessing age (Table 2.2) also showed no difference in
effect within age groups when comparing statins to non-statins or non-statins to nonusers. However, patients under the age of 65 in the statins vs. non-users group had
improved survival while those over the age of 65 did not.
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Figure 2.2: One-year survival analysis. Hazard ratios (HR) and associated 95%
confidence intervals (CI) for the effect of treatment group on survival within the
propensity-matched sample. Matching was conducted for each treatment group analysis.
(*) signifies statistically significant result.
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Figure 2.3: The effect of dose intensity on one-year survival. Statin exposure groups
limited to medium and high dosages. The distribution of low, moderate and high dosage
statins prior to matching is 7,918, 46,152 and 11,307, respectively. Hazard ratios (HR)
and associated 95% confidence intervals (CI) for the effect of treatment group are
presented. (*) signifies statistically significant result.
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Table 2.2: Age sensitivity analysis for all exposure group analyses. Hazard ratios (HR)
and associated 95% confidence intervals (CI) for the effect of treatment group are
presented.
Statins Vs. Non-Statins
Age
< 65 Yrs
65-75 Yrs
>75 Yrs

HR
0.67
1.17
1.22

95% CI
0.40
1.10
0.92
1.48
0.96
1.56

Statins Vs. NonUsers
HR
95% CI
0.71
0.55 0.92
0.94
0.84 1.05
0.91
0.82 1.01
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Non-Statins Vs.
Non-Users
HR
95% CI
0.79
0.54 1.17
0.93
0.72 1.20
0.77
0.59 1.01
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To examine differences among individual statins (Figure 2.4), we stratified molecules by
natural and synthetic origin. Compared to simvastatin as reference, the more hydrophilic
rosuvastatin (HR 1.21, 95% CI 1.03-1.43) and fluvastatin (HR 2.18, 95% CI 1.36-3.50)
molecules were associated with a higher rate of death with no differences between other
products, i.e. simvastatin is associated with a protective effect. When grouped by type,
natural statins had a marginally protective effect on survival, but this was not statistically
significant (HR=0.91, 95% CI 0.83-1.01)

Bisphosphonate users (n=4,528) were compared to non-users and stratified by statin
use. Among all cancers, bisphosphonates had a non-significant reduction in death when
compared to non-users (HR 0.82, 95% CI 0.65-1.03) (Figure 2.5). Stratification by
cancer type could not be completed due to limited population size. A treatment group
consisting of patients using both statins and bisphosphonates (n=4,090) exhibited a
much larger improvement in survival compared to a subset of non-users that did not
receive either medication (HR 0.60, 95% CI 0.45-0.81).

The majority of subjects remained on statin therapy with an average of 78.3% of days in
the post-index period covered by statin therapy and only 19 out of 65,440 patients
stopped statin therapy after cancer diagnosis. More than half of this treatment group
received statins for the entire follow-up period. Generally, we observed that the statin
cohort continued on statin therapy for the majority of their post-diagnosis follow-up time.
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Figure 2.4: The effect of statin stratification by type and class on one-year survival. In
comparison by type, simvastatin was used as reference. In comparison by class,
synthetic statins were used as reference. The list of natural statins included lovastatin,
pravastatin and simvastatin. Synthetic statins included rosuvastatin, atorvastatin,
fluvastatin and pitavastatin. Hazard ratios (HR) and associated 95% confidence intervals
(CI) for the effect of treatment group are presented.

Simvastatin
Lovastatin
Pravastatin
Rosuvastatin
Atorvastatin
Fluvastatin
Pitavastatin
Synthetics
Natural

N
28,714
3,935
7,307
6,492
18,443
372
112
25,419
39,956

HR
Ref
0.97
1.01
1.21
1.04
2.18
0.41
Ref
0.91

95% CI
Ref
0.77
0.85
1.03
0.92
1.36
0.06
Ref
0.83

Ref
1.21
1.19
1.43
1.17
3.50
2.91
Ref
1.01
0 .1
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Figure 2.5: The effect of synergistic statin combinations on one-year survival.
Bisphosphonates assessed in the analysis were alendronate sodium, etidronate
disodium, ibandronate sodium, pamidronate disodium, risedronate sodium and
zoledronic acid. Bisphosphonates and dipyridamole users were required to have at least
a 90 cumulative days supplied in the 6 months prior to cancer diagnosis. Hazard ratios
(HR) and associated 95% confidence intervals (CI) for the effect of treatment group are
presented. (*) signifies statistically significant result.
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D. DISCUSSION

This observational cohort study used epidemiological data and identified a significant
effect on the overall survival of cancer patients who receive statins at the time of
diagnosis. This advantage was specific to cancers of the lung, kidney, and leukemias. In
addition, the concurrent use of a bisphosphonate with a statin was associated with an
improvement in overall survival, but stratification by cancer type was not possible due to
the small sample size. This observation is consistent with the mechanisms of action of
the two agents suggesting the theoretical potential for synergy in a prospective study.
The effect of dipyridamole in combination with statin was not significant in the small
cohort of patients receiving this combination (n=651). The effect of statins was
comparable to other cholesterol-lowering medications, which is consistent with a recent
cohort study in postmenopausal women showing that regular use of statins or other-lipidlowering medications was associated with decreased cancer death (111). Multiple
systems or pathways may explain the mechanism by which statins induce their effect on
cancer survival including inhibition of Ras, improvement of immune surveillance, and the
reduction of venous thromboembolisms (VTE).

Statins impact normal cell survival mechanisms including cell proliferation, pro-apoptotic
effects, induction of autophagy, and anti-invasive and anti-migration effects that have
been systematically studied in in vitro and in vivo models systems. The overarching
hypothesis is the potential effect of statins on the Ras signaling pathway (163-169). Lung
cancer, pancreatic cancer and hematopoietic/lymphoid cancers are associated with high
rates of K-Ras mutation (38%, 63% and 21%, respectively) (170). High frequency of
mutation may explain why patients with these cancers benefited in our analysis.
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However, our results did not show an effect in colorectal cancer, which also has a high
frequency in K-Ras mutation (170). Stain-use following diagnosis was previously shown
to reduce colorectal cancer–specific mortality (119) and the prospective use of
simvastatin with cetuximab/irinotecan in K-Ras mutant patients had favorable disease
control rate (129). Considering in vitro evidence, statin-mediated modulation of protein
prenylation in cancer cells requires suprapharmacologic concentrations (e.g., 1-25µM)
for prolonged periods (171-174). Previous studies from our group demonstrated high
(7.5mg/kg b.i.d.) simvastatin doses, ~25-fold of the typical daily dose (i.e., 40mg),
achieved maximum plasma concentrations that were in the range of 0.08-2.2µM (175).
Consistent with this, our results show that the dose-intensity of typical dosages
cholesterol lowering treatment does not impact overall survival, suggesting other
mechanisms may be involved.

Prior studies have suggested the immuno-stimulatory effects of statins as the
mechanism for anti-cancer activity. By inhibiting the mevalonate pathway, statins can
induce innate lymphocyte activation and increase immune surveillance. Depletion of
prenyl pyrophosphates in human dendritic cells generates danger signals that can
translate into caspase-1 activation. Caspase-1 cleaves interleukin-1-beta (IL-1β) and IL18 into their activated forms allowing the release of cytokines that include interferon-γ
and IL-2 (176). Statin-induced activation of IL-2 primed γδ T cells and natural killer cells
exhibit potent antitumor cytotoxicity and ectopic GGPP reintroduced into the cell culture
abolishes this effect (177, 178). Immunomodulation may be an important contributor as
immune cells are more likely to be exposed to higher statin concentrations than cancer
cells.
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Finally, given the lack of difference between statin and non-statin drugs, the survival
effect may in part be due to reductions in thrombotic events. Observational studies show
that statins lower the risk of VTE in the cancer population, thereby increasing OS (179).
In a prospective observational cohort of 1,434 cancer patients, VTEs occurred in 2.94%
of patients at 12 months and 3.54% at 24 months for statin users. In comparison, those
who were not treated with statins had elevated rates of VTE of 7.13% at 12 months and
8.13% at 24 months (P= 0.04). Among newly-diagnosed cancer patients who were
prospectively followed for a two-year period, statins users had a lower risk of VTE than
non-users (HR 0.43, CI 0.19 to 0.98). In contrast, a meta-analysis of 27 trials assessing
the effect of statin use and the lowering of LDL cholesterol on cancer incidence and
mortality found a lack of effect after a median of five years of therapy, but a small effect
within the first year after diagnosis (180). In the ACALM study, hyperlipidemia was
associated with a significantly reduced mortality rate in lung, breast, prostate and bowel
cancers (181). With respect to age, our analyses shows that those over 65 had no
significant benefit from statin treatment, which may be the result of an overall increased
VTE risk in that population. More work is needed to understand how cholesterol lowering
medications impact the risk of thrombotic events in cancer and whether this effect
explains part of the overall protective effect observed in this study.

This study is subject to the limitations of all claims-based studies (182, 183). Claims data
lack detailed information on laboratory values or tumor staging, which may have
influenced the outcomes of this study. This study was limited to a one-year follow-up due
to the availability of data and the heterogeneity and time-varying confounded with longer
follow-up. Lastly, while propensity score matching is known to reduce selection bias in
non-randomized studies, it is possible that residual bias is present or that unmeasured
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confounders may have impacted these findings (158). This study is strengthened by a
large sample size, inclusion of minimum medication exposure criteria (e.g. 90 days
supplied), and by inclusion of an active control group, which are often lacking in similar
studies.

E. CONCLUSION

Epidemiological health outcomes data can be used to test hypotheses based on the
effect of drugs on specific biological pathways and processes. Our work shows that the
use of statins alone and in combination with bisphosphonates could provide a survival
benefit in certain cancers. We have shown the applicability of health outcomes research
in the assessment of response dependent on differing exposure groups.

Copyright © Sherif M. El-Refai 2017
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CHAPTER 3
A. OVERVIEW

Immune checkpoint inhibitors (ICI) are designed to restore a patient’s antitumor immune
response, which has been attenuated during the process of tumor development. Antigen
presenting cells (APC) normally express programmed death ligand 1 (PD-L1) that, when
bound by PD-1 on T cells, signal an exhausted active immune response. In cancers that
express PD-L1 on tumor cells, PD-1 receptor expressed on T cells, B cells, and NK cells
of an activated immune system, and the interaction of PD-1 and PD-L1 characterize an
adaptive and immune-evasive response by the tumor. This immune-evasive interaction
can be reversed by addition of ICIs that inhibit either molecule (53). Recently, agents
that modulate the tumor immune response have provided durable clinical benefit to
patients with late-stage or recurrent disease. Nivolumab (Opdivo®) has received FDA
approval for the treatment of squamous and non-squamous metastatic non–small cell
lung cancer (NSCLC) and metastatic renal cell carcinoma with progression on or after
chemotherapy (184). Nivolumab is a human IgG4 antibody that blocks programmed
death 1 (PD-1) receptor and potentiates activation of T cells (185). Nivolumab therapy
demonstrated improved tumor-related outcomes in multiple types of cancer (186).
Pembrolizumab (Keytruda®), another PD-1 inhibitor, received FDA approval to treat
advanced (metastatic) NSCLC whose disease has progressed after other treatments
and with tumors that have 50% programed death ligand 1 (PD-L1) expression (187).
PD-1 inhibition facilitates activation of potentially autoreactive T cells, leading to
inflammatory adverse events across a range of tissues. Patients with a history of
autoimmune diseases were excluded from clinical trials of PD-1 inhibitors (188).
Exclusions included multiple sclerosis, autoimmune neuropathy, Guillain-Barre
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syndrome, myasthenia gravis, systemic lupus erythematosus, connective tissue
diseases, scleroderma, inflammatory bowel disease, Crohn’s disease, ulcerative colitis,
and hepatitis. Patients with rheumatoid arthritis, Sjogren’s syndrome, and psoriasis were
included if disease was well-controlled. Although these therapies hold great promise,
ICIs can trigger a variety of immune-related adverse events (irAEs). These include
dermatologic, gastrointestinal, hepatic, endocrine, and other inflammatory conditions and
they are believed to result from general immune response enhancement (189). Khan et
al have shown a relatively high rate of autoimmune diseases, approximately 14%,
among lung cancer patients, and these patients were more likely to be older females
(190). The objective of this study was to confirm findings of Khan and colleagues in a
more diverse cohort and identify whether cancer patients with autoimmune disease
exhibit different baseline characteristics and comorbidities.

B. METHODS

We identified lung and renal cancer patients using Truven Health MarketScan
Commercial Claims and Medicare Supplemental Database. The Marketscan database
includes approximately 40 million individuals from over 160 large employers and health
plans across the US and includes healthcare claims with diagnosis and procedure codes
for medical encounters and all prescription medication fills. These data are de-identified
in compliance with the Health Insurance Portability and Accountability Act regulations
(HIPAA) and the University of Kentucky Institutional Review Board approved the use of
the database for this study.
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Adults 18 years and older diagnosed with cancer between January 1, 2010 and
November 31, 2013 were identified. At least 2 inpatient or outpatient diagnoses
separated by at least 14 days were required and the date of the first qualifying diagnosis
of cancer was defined as the index date. We directed our analyses to only lung and
renal cancer due to the initial approvals of the immune checkpoint inhibitor, nivolumab.
Nivolumab received approval for the treatment of metastatic non-small cell lung cancer
on March 4, 2015 and for metastatic renal cell carcinoma on November 23, 2015.
Patients were required to have at least 12 months of pre-index and a minimum of onemonth post-index continuous enrollment in the database. We assessed patients for
diagnosis of autoimmune diseases prior to or after diagnosis of cancer using ICD-9
codes for 41 autoimmune diseases. It is necessary to assess autoimmune disease
before and after diagnosis because newly diagnosed autoimmune conditions would still
have bearing on therapeutic decision-making practices. Prevalence was determined by
the presence of 2 or more claims to autoimmune diseases separated by at least 30
days. Baseline characteristics and Elixhauser and Charlson comorbidity indexes of
patients with and without autoimmune diseases were compared. These indexes include
17 and 31 categories of comorbid conditions, respectively, and have been widely used
for risk adjustment with health outcomes data (154, 155). Two sample t-test and chisquare tests were conducted to assess significant differences between groups.
Bonferroni correction was applied due to multiple comparisons.

C. RESULTS

We identified 53,783 lung cancer patients and 27,349 renal cancer patients of whom
13,156 (24.5%) and 8,217 (30.1%) also had an autoimmune disease, respectively.
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Hypothyroidism (55.8%, 56.7%), rheumatoid arthritis (20.2%, 18.1%) and type 1
diabetes mellitus (11.5%, 14.5%) were the most common for both lung and renal cancer
patients respectively (Table 3.1). Baseline characteristics and comorbidities are listed in
Table 3.2. Cancer patients with autoimmune disease were more likely to be female,
older and had higher prevalence of comorbidities than cancer patients without
autoimmune disease (Table 3.2).
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Table 3.1: Autoimmune (AI) disorders in lung and renal cancer patients between the
years 2009-2013.

Autoimmune Disorder
Rheumatoid Arthritis
Psoriasis
Systemic Lupus Erythematous
Systemic Sclerosis
Sicca Syndrome
Autoimmune NOS
Autoimmune Hepatitis
Primary Biliary Cirrhosis
Celiac Disease
Ankylosing Spondylitis
Polymyalgia Rheumatica
Addison's Disease
Ulcerative Colitis
Crohn's Disease
Meniere's Disease
Hashimoto's Disease
Polyartheritis Nodosa
Giant Cell Arthritis
Pernicious Anemis
Autoimmune Hemolytic Anemia
Idiopathic Thrombocytopenic Purpura
Thyrotoxicosis
Multiple Sclerosis
Iridocyclitis
Pemphigus
Eczema
Alopecia Areata
Vitiligo
Wegener's Granulomatosis
Dermatopolymyositis
Myasthenia Gravis
Scleroderma
Antiphospholipid
Guillian-Barre Syndrome
Type 1 Diabetes Mellitus

Among Lung CA
Patients with AI
Disease. N (%)
2,653 (20.2)
527 (4.0)
225 (1.7)
78 (0.6)
115 (0.9)
37 (0.3)
59 (0.5)
38 (0.3)
71 (0.5)
506 (3.9)
227 (1.7)
357 (2.7)
352 (2.7)
258 (2.0)
89 (0.7)
89 (0.7)
174 (1.3)
93 (0.7)
710 (5.4)
39 (0.3)
152 (1.2)
157 (1.2)
200 (1.5)
280 (2.1)
32 (0.2)
312 (2.4)
34 (0.3)
18 (0.1)
28 (0.2)
33 (0.3)
89 (0.7)
62 (0.5)
3 (0.0)
28 (0.2)
1,507 (11.5)
56

Among Renal CA
Patients with AI
Disease. N (%)
1490 (18.1)
402 (4.9)
120 (1.5)
20 (0.2)
70 (0.9)
20 (0.2)
72 (0.9)
33 (0.4)
51 (0.6)
402 (4.9)
141 (1.7)
196 (2.4)
238 (2.9)
208 (2.5)
67 (0.8)
67 (0.8)
89 (1.1)
45 (0.6)
301 (3.7)
22 (0.3)
82 (1.0)
100 (1.2)
103 (1.3)
209 (2.5)
33 (0.4)
288 (3.5)
26 (0.3)
29 (0.4)
21 (0.3)
10 (0.1)
58 (0.7)
47 (0.6)
5 (0.1)
23 (0.3)
1,189 (14.5)
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Hypothyroidism
Hyperthyroidism
Sweet's Syndrome
Sjogren's Syndrome
Pyoderma Gangrenosum
Sarcoidosis

7,334 (55.8)
157 (1.2)
215 (1.6)
115 (0.9
7 (0.1)
249 (1.9)
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4661 (56.7)
100 (1.2)
183 (2.2)
70 (0.9)
1 (0.0)
129 (1.6)
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Table 3.2: Baseline characteristics and comorbidities between lung and renal cancer
patients with or without autoimmune disease.
Cancer W/
Autoimmune

Cancer W/O
Autoimmune

N (21,373)

%

N (59,759)

%

P Value

8,393
6,439
3,545
2,996
12,133
2,938
5,530
2,986
1,150
5,812

39.3
30.1
16.6
14.0
56.8
13.8
25.4
14.0
5.4
27.2

25,672
16,762
9,276
8,049
25,140
6,860
13,659
6,920
2,953
14,187

43.0
28.1
15.5
13.5
42.1
11.5
22.9
11.6
4.9
23.7

<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
<.0001
0.0119
<.0001

13,814
2,375
211
1,919
9,063
3,085
2,528
308
33
4,340
1,145
1,598
1,599
3,549
990
1,358
278
246
397
2,713
5,791

64.6
11.1
1.0
9.0
42.4
14.4
11.8
1.4
0.2
20.3
5.4
7.5
7.5
16.6
4.6
6.4
1.3
1.2
1.9
12.7
27.1

35,614
5,067
584
4,231
25,053
6,130
6,767
772
116
15,952
2,332
3,402
4,778
8,679
2,075
2,835
1,087
624
1,148
5,888
14,702

59.6
8.5
1.0
7.1
41.9
10.3
11.3
1.3
0.2
26.7
3.9
5.7
8.0
14.5
3.5
4.7
1.8
1.0
1.9
9.9
24.6

<.0001
<.0001
0.899
<.0001
0.2219
<0.0001
0.047
0.1032
0.2445
<.0001
<.0001
<.0001
0.0165
<.0001
<.0001
<.0001
<.0001
0.1933
0.5595
<.0001
<.0001

Age Categories
< 65 Yrs
65 to 74 Yrs
75 to 80 Yrs
>80 Yrs
Gender (F)
CHF
Arrhythmias
Valvular disease
Pulmonary Circulation
Peripheral Vascular
Hypertension
uncomplicated
Hypertension complicated
Paralysis
Other neurological
Chronic pulmonary
Renal failure
Liver disease
Peptic ulcer disease
HIV/AIDS
Metastatic Cancer
Coagulopathy
Obesity
Weight Loss
Fluids and Electrolytes
Blood Loss Anemia
Deficiency Anemia
Alcohol Abuse
Drug Abuse
Psychoses
Depression
CHD
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More than a quarter of patients diagnosed with lung and renal cancer were found to
have a comorbid autoimmune condition. When considering that immune checkpoint
inhibition is only approved in late stages of cancer, it is not clear whether the benefits of
pursuing treatment in patients with autoimmune disease outweigh the risk of inducing
worse irAEs. Several case reports have been published showing that while
discontinuation of the immune checkpoint inhibitor results in resolution of the irAE, long
courses of medications specific to the autoimmune reaction may be needed to mitigate
the effects of ICI therapy (191-193). In a large systematic review of 251 cases involving
anti-CTLA-4 and anti-PD-1 agents, approximately 52% of treated patients discontinued
ICI therapy due to the irAEs.(191) Less than 10% required no treatment for the irAE,
while the remainder was treated with corticosteroids, infliximab (an anti-tumor necrosis
factor (TNF) agent), or disease-modifying anti-rheumatic drugs (DMARDs). Death due to
the irAEs occurred in 4.7% of patients. Cutaneous autoimmune reactions are commonly
associated with ICI therapy, but a case report on two patients with metastatic melanoma
illustrated that irAEs may not appear until long after initiation of therapy.(193) An autopsy
study presented an elderly melanoma patient exhibiting a systemic inflammatory
response that affected multiple organ sites ultimately resulting in the death of the patient
(194).

This study is subject to the limitations of all claims-based studies (182, 183). Notably,
claims data lack detailed information on laboratory values or information on tumor
staging, which may have influenced the outcomes of this study. This study was limited to
a one-year follow-up due to the availability of data and the heterogeneity and timevarying confounded with longer follow-up. This study is strengthened by a large sample
size and the inclusion of both commercial and medicare claims.
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D. CONCLUSION

The exclusion of patients with autoimmune conditions from the approval studies of
nivolumab and pembrolizumab resulted in a lack of clinical guidance for a large
population of patients that oncologists must decide whether to treat or not. In late stage
treatment of these cancers, the potential durable response associated with immune
checkpoint inhibitors will need to be weighed against the worsening of the patient’s
autoimmune condition, a decision for which clinical trials have not provided a concrete
answer. Future evaluation of real-world treatment patterns will be needed to assess ICI
usage and response in patients with autoimmune conditions.

Copyright © Sherif M. El-Refai 2017
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CHAPTER 4
A. OVERVIEW

Immune checkpoint inhibitors (ICI) are designed to restore a patient’s antitumor immune
response, which has been attenuated during the process of tumor development. Antigen
presenting cells (APC) normally express programmed death ligand 1 (PD-L1) that, when
bound by programmed death 1 receptor (PD-1) on T cells, signal an exhausted active
immune response. In cancers that express PD-L1 on tumor cells, PD-1 receptor
expressed on T cells, B cells, and NK cells of an activated immune system, and the
interaction of PD-1 and PD-L1 characterize an adaptive and immune-evasive response
by the tumor. Cytotoxic T lymphocyte-associated molecule-4 (CTLA-4) is a homolog to
CD28 and competitively binds to B7 on antigen-presenting cells providing a co-inhibitory
signal, preventing the priming and activation of CD8+ T cells (195). These immuneevasive interactions can be reversed by addition of ICIs (53). These agents that
modulate the tumor immune response have recently provided durable clinical benefit to
patients with late-stage or recurrent disease.

To date, nivolumab (Opdivo®) has received FDA approvals for the treatment of
squamous and non-squamous metastatic non–small cell lung cancer (NSCLC),
metastatic renal cell carcinoma, advanced melanoma, Hodgkin lymphoma, previously
treated locally advanced or metastatic urothelial carcinoma, hepatocellular carcinoma
patients previously treated with sorafenib and microsatellite instability-high (MSI-H) or
mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has
progressed following treatment with a fluoropyrimidine, oxaliplatin and irinotecan (184,
186). Nivolumab is a human IgG4 antibody that blocks PD-1 and potentiates activation
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of T cells (185). Pembrolizumab (Keytruda®), also a PD-1 inhibitor, received FDA
approval for the treatment of advanced (metastatic) NSCLC that has progressed after
other treatments and for tumors with at least 50% expression of programmed death
ligand 1 (PD-L1) by tumor cells. Specifically, advanced melanoma, metastatic head and
neck squamous cell carcinoma, classical Hodgkin lymphoma, advance or metastatic
urothelial carcinoma, gastroesophageal junction cancer whose tumors express PD-L1,
and metastatic solid tumors that are MSI-H or dMMR are eligible for this therapy (187).

The only approved biomarker of response for any ICI is measurement of PD-L1
expression from the tumor. The Keynote-001 trial sought to correlate response to MK3475, a PD-1 inhibitor, with expression of PD-L1. In the melanoma arm, PD-L1
expression on tumor cells increased the response rate in 49% compared with 13% of
PD-L1 negative patients. The NSCLC arm of this study showed that when greater than
50% of tumor cells expressed PD-L1, response to MK-3475 was predicted and this was
observed in nearly 25% patients. For all patients, response rate to MK-3475 was about
19%, irrespective of PD-L1 expression in the tumor. Median progression free survival
(PFS) was 14.1 months in PD-L1 strongly positive patients compared with 9.3 months in
the weakly positive population (56). These findings preclude PD-L1 expression from
being an exclusionary predictive biomarker. The limitations of this assay include timing
of tissue acquisition, tumor heterogeneity, and timing of therapy relative to the
expression of PD-L1 suggesting that finding a more robust biomarker of response is
needed.

Applying precision medicine principles to immuno-oncology requires the discovery of
biomarkers that can identify the patients most likely to benefit from this class of
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treatment. Robust biomarkers need to encompass an efficient, repeatable and easily
accessible source of biological data from the patient. Determination of PD-L1 expression
requires direct sampling of tumor tissue from a patient which necessitates an invasive
procedure. If samples banked early during treatment and then used later to determine
expression levels, the assayed expression levels may not represent the tumor or
metastases in the current state. Predictive biomarkers that can be measured from
peripheral blood sampling allow the inclusion of this tool into clinical practice with
minimal workup, allow for assay immediately prior to initiation of ICI treatment, and can
be repeated throughout therapy for monitoring purposes. I sought to determine whether
peripheral factors associated with the patient’s immune response or malignancy that
have the precision and robustness to be more predictive than PD-L1 expression for
anticipating response to PD-1 inhibitor therapy.

Several comorbid conditions have been associated with the development and
progression of cancer but the long-term effect on the immune system may also impact
response to ICI treatment (196). It is estimated that potentially 25% of all malignancies
develop after exposure to chronic inflammation and to viral and bacterial infections that
initiate an immune response (197). Chronic inflammation encompasses multiple
conditions. Metabolic syndrome, one family of chronic inflammatory diseases, has
consistently been correlated with the development of several tumor types. Worldwide
there are over 312 million people with a BMI>30 kg/m2 and within the last four decades,
the prevalence of obesity has amassed to approximately 50% of adults within the US
(198). Obese patients develop more localized tumors, have earlier relapse, and a
diminished overall survival (199). Hyperlipidemia includes low high-density-lipoprotein
(HDL) cholesterol and elevated low-density lipoprotein (LDL) cholesterol. Low HDL and
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high serum levels of total cholesterol have been associated with higher incidence of
lung, prostate and post-menopausal breast cancer (200, 201). This study followed over 1
million patients for 16 years who had no reported history of cancer and identified that,
independent of high body mass, type 2 diabetes mellitus (T2DM) is a predictor of
mortality in pancreatic, breast, liver and bladder cancer (202). The potential causal link
between metabolic syndrome, inflammation and cancer is adipose tissue hypoxemia
(203). This phenotype is characterized by inflammatory cytokines in plasma and the
adipose tissue itself as well as macrophage infiltration and activation.

Immune cells secrete specific cytokines and chemokines that act as survival and
proliferation factors for the promotion of malignant tumor cells. The presence of
inflammation and the secretion of inflammatory mediators can lead to the induction of
transcription factors such as NF-κβ. In the initial phase of tumor development,
inflammatory mediators such as cytokines, reactive oxygen species (ROS), and reactive
nitrogen species (RNS) derived from tumor-infiltrating immune cells induce epigenetic
alterations in pre-malignant lesions and silence tumor suppressor genes (204).
Accumulation of microbial pathogens and tissue necrosis activate transcription factors
that are necessary for the expression of pro-angiogenic factors (IL-8, VEGF), growth
factors (IL-6, GM-CSF), anti-apoptotic factors (Bcl-XL, c-FLIP), invasion-promoting
factors (MMP-2, MMP-7, MMP-9, uPA), inflammatory enzymes (PGHS-2, LOX),
prostaglandins, iNOS, chemokines (CCL2, CCL20, IL-8), and pro-inflammatory cytokines
(IL-1, IL-6, IL-23, TNF, TGF-β, EGF) that support the malignant phenotype (205). Of the
cytokines released, transforming growth factor beta (TGF-β) and tumor necrosis factor
alpha (TNF-α) help activated NF- κβ in a process called epithelial-mesenchymal
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transition (EMT). EMT is a process necessary for tumor invasiveness and metastasis to
other sites (206).

While we understand that a pro-inflammatory cytokine-rich environment promotes the
formation of some tumor types, we are interested in understanding whether these
cytokines induce adaptive immune resistance in lung cancers. If true, patients with an
inflammatory cytokine-rich periphery may respond well to certain immune checkpoint
inhibitors. Importantly, PD-L1 expression is induced by interferon (IFN) activity, and
indirectly by IL12, in both endothelial and breast cancer cells (207, 208). Further, Taube
and colleagues investigated the signaling events that induce PD-L1 expression and
demonstrated that many cytokines were overexpressed expression in melanoma cell
lines, including RANTES, CXCL1, IL10, IL18 and IL21. In vitro stimulation of melanoma
cells by IFN-γ induced PD-L1, but recombinant forms of the other cytokines failed to
increase cell surface expression of PD-L1 with or without IFN-γ (54). In a separate study,
incubation of activated T-cells with IL10 (+/- IFN-γ) induced expression of PD-L1 on
monocytes thereby reducing T-cell activation (51). Increased expression of these
molecules correlates with increased T cell infiltration (209, 210). Because PD-L1
expression is modulated by the interferons (α, β, and γ) in a dose- and time-dependent
manner as measured by both mRNA and cell surface expression, regulation of this
molecule is important for maintaining control of the immune response and is dependent
on peripheral cytokines (207).

Inflammatory diseases are, in part, caused by poor lifestyle choices and can contribute
to cancer development. Paradoxically, the presence of inflammatory diseases may serve
as biomarkers of durable response to immune checkpoint inhibitors. Given these
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studies, there is a fundamental gap in understanding of the timing of expression of PDL1 in NSCLC tumors and PBMC and how those levels relate to the state of the
inflammatory response and response to ICI. To measure the relationship between
chronic inflammation and the response to ICIs, we investigated the following two aims:
•

Retrospective analysis of local Markey Cancer Center (MCC) data for a history
of chronic inflammation and correlate with response to nivolumab therapy in
NSCLC patients

•

Assess national healthcare claims data to determine if ICI-treated patients with a
history of chronic inflammation exhibited improved overall survival

Health outcomes research is a methodology used to identify and measure the link
between treatments or interventions and the desired outcome of interest. With the
limited, real-time clinical applicability of basic science research and the constraints of
expensive, time-consuming and limited populations of clinical trials, health outcomes
data research bridges the gap to identify the most effective intervention. Health
outcomes research can be used to identify disparities among different populations and
further patient-centered outcomes. Advances in bioinformatics using a “Big Data”
approach provide an opportunity for novel insights regarding the discovery of biomarkers
of response (211). Researcher are now able to use real-world data to conduct high
quality investigations that demonstrate the value of this novel class of treatment and the
variables that influence its success. The combination of epidemiological evidence and
preclinical data will provide strong rationale for future prospective clinical studies.
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B. METHODS

Retrospective Study Subjects and Methods
Metastatic NSCLC-diagnosed patients treated at the MCC with nivolumab were
retrospectively identified between March 2015 and February 2016 using an institutional
IRB-approved study. The study was deemed as minimal risk and was exempt from
obtaining informed consent from study patients. The range of dates chosen covered the
span of time from the FDA approval of nivolumab treatment for patients diagnosed with
metastatic NSCLC with progression on or after platinum-based chemotherapy in NSCLC
to the date this study was conducted. The data were gathered by reviewing electronic
medical records. Data collected included gender, age, comorbid condition history,
previous chemotherapy treatment, nivolumab treatment start date and number of cycles
of therapy completed. Cycles of nivolumab therapy received were utilized as a surrogate
for response. Patients treated with 6 cycles or more of therapy were considered to have
a robust, objective response. Chronic inflammatory conditions collected included the
diagnosis of hyperlipidemia, hypertension, diabetes mellitus, obesity or chronic
obstructive pulmonary disorder (COPD). No statistical analyses or power calculations
was undertaken.
Tumor Acquisition & PD-L1 Expression
Using the identified patients treated with nivolumab, the MCC Biospecimen and Tissue
Procurement Shared Resource Facility was used as an honest-broker to query for
formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples associated with each
patient. Of the 45 patients for which health history was collected, PD-L1 expression was
assessed for each tumor sample retrieved. The PD-L1 IHC 28-8 pharmDx assay is
approved by the US Food and Drug Administration (FDA) as a complementary
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diagnostic for non-squamous NSCLC and melanoma in the USA (212). The rabbit
monoclonal antihuman PD-L1 antibody 28-8 was produced by Abcam (San Francisco,
CA, USA). The 28-8 antibody was tested using Dako PD-L1 IHC 28-8 pharmDx (Dako
North America; SK005) and the Dako-recommended protocol, as previously described
(213). Tumor tissue sections were de-paraffinized and antigen-retrieval was initiated at
97 °C for 20 min. Detection of PD-L1 protein was conducted using 2 µg/mL of the
antibody on the Autostainer Link 48 according to Dako instructions. Upon completion,
the stained sample slides were sent to Kimberly Abshear M.D. of UK Pathology to
measure the expression level of PD-L1 and to determine the histology as either
squamous or non-squamous carcinoma.
Outcomes Study Subjects
For the health outcomes research aim of this study, the Truven Health MarketScan
Commercial Claims and Medicare Supplemental Databases was used to complete the
outcomes aim of this study. The Marketscan database includes approximately 40 million
individuals from over 160 large employers and health plans across the United States and
includes healthcare claims with diagnosis and procedure codes for medical encounters
and all prescription medication fills. Data are de-identified in compliance with the Health
Insurance Portability and Accountability Act regulations (HIPAA), and the University of
Kentucky Institutional Review Board previously provided blanket approval the use of the
database for studies conducted by UK researchers. Adults aged 18 years and older
treated with an ICI between January 1, 2013 and December 31, 2015 were identified
using J codes associated with the medications. The healthcare common procedure
coding system (HCPCS) is a standardized coding system, including current procedural
terminology (CPT) codes and J codes, which is used to identify products, supplies or
services. Patients were required to have at least 24 months of pre-index and a minimum
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of one-month post-index continuous enrollment in the database (Figure 4.1). Patients
were diagnosed with one of the following types of cancer as categorized using the
international classification of diseases, ninth revision (ICD-9) codes: Lung cancer (162.2
– 162.9) or Melanoma (172.0-172.9) (214). The ICIs included were nivolumab (C9453,
J9299), pembrolizumab (C9027, J9271), and ipilimumab (J9228). At least two inpatient
or outpatient diagnoses within 14 days were required, and the date of the first qualifying
diagnosis of cancer was defined as the index date. Exposure groups were defined as:
ICI-treated patients with a history of chronic inflammatory conditions or ICI-treated
patients without a history of chronic inflammatory conditions. Chronic inflammatory
conditions included the diagnosis of hyperlipidemia, hypertension, obesity, diabetes
mellitus or chronic obstructive pulmonary disorder (COPD).
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Figure 4.1: Health outcomes data analysis timeline and process.

Outcomes Analysis – Overall
Survival

24-Month PreIndex

Pre-Index

ICI-Treated
Population
(All Cancers)

Stratify by Chronic Inflammatory Condition,
Propensity-score matching with CCI &
Previous Therapies

12-Months Post-Index

Truven claims data stratification and analysis approach. An illustration
representing the manner in which the desired patient population was identified
under Truven and how the relationship between chronic inflammatory
conditions and ICIs are assessed.
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Outcomes Data Measures & Statistical Methods
Patient demographic characteristics included age, gender, geographic region and urban
residence. Clinical characteristics measured during the 24-month pre-index period
included previous chemotherapy treatments, previous radiation exposure, and the
Charlson Comorbidity Index (CCI) (154). CCI includes 17 categories of comorbid
conditions, respectively, and are widely used for risk adjustment with health outcomes
data. Presence of metastatic disease was assessed on the index date. The outcome of
interest is one-year overall survival. Pairwise analyses were carried out between the two
exposure groups: ICI-treated patients with a history of a chronic inflammatory disorders
versus ICI-treated patients without a history of chronic inflammatory disorders.
Propensity score matching was conducted using baseline comorbidities, medications,
and demographic information to achieve balance between treatment groups. Propensity
scoring mimics the randomization process of a clinical trial so that each matched pair
has the same baseline probability to receive either treatment (156-158). Matched pairs
should be similar in all baseline characteristics. Patients with the same cancer type were
matched using a greedy, nearest neighbor algorithm with a caliper set at 0.2 times the
standard deviation of the propensity scores in the sample, allowing for up to five
matches for each treated person (159). Standardized differences were calculated. A
standardized difference of <0.10 is generally considered to be non-significant (160). To
address any residual confounding after propensity score matching, covariates were also
incorporated in the final regression models (157). The final model included the following
adjustment covariates: age, CCI score, gender, region, urban, myocardial infarction,
congestive heart failure, peripheral vascular disease, cerebrovascular disease,
chemotherapy and radiation.
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Cox proportional hazard regression models, accounting for correlation within matched
pairs, were used to assess risk of death within one year of diagnosis among all cancers
and then stratified among each cancer. Follow-up was terminated for those surviving
beyond one year and were censored. Hazard ratios (HR) and 95% confidence intervals
(CI) are reported. A p-value of <0.05 is considered statistically significant. All matching
and statistical analyses were conducted in SAS.

C. RESULTS

Identification of chronic inflammatory diseases as precursor to response in MCC
patients
We identified 45 patients diagnosed with metastatic NSCLC treated with nivolumab
between the dates of March 2015 and February 2016. The average number of cycles of
nivolumab therapy administered for all 45 patients is 5.49 with a standard deviation of
5.03 (Figure 4.2). Nine patients achieved long-term objective response (Mean=8.5
cycles, SD=1.2), representing 20% of the patient population. Consistent with prior
studies, approximately 20% of treated patients achieved an objective response/clinical
benefit (> 6 cycles of nivolumab) in the absence of molecular selection for therapy (47,
215). Of the 45 patients, twenty-nine had at least one, pre-existing, comorbid, chronic
inflammatory condition. Eleven patients had two or more chronic inflammatory
conditions. Patients with no history of chronic inflammatory conditions averaged 3.88
cycles of nivolumab treatment (SD = 0.28), those with at least one chronic inflammatory
condition averaged 6.38 cycles of therapy (SD = 0.89), and lastly those patients with a
history of two or more chronic inflammatory conditions averaged 8.45 cycles of
nivolumab treatment (SD = 1.02) (Figure 4.3).
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# Cycles of Nivolumab

Figure 4.2: MCC nivolumab-treated patients treated March 2015 to February 2016.
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# Cycles of Nivolumab Treatment

Figure 4.3: The effect of chronic inflammatory conditions on cycles of nivolumab.
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PD-L1 expression of tumor tissue analysis
Seven patients were found to have banked FFPE lung tumor tissue samples in the MCC
biospecimen core. No information was present as to when sample was isolated during
the patient’s treatment history. Three patients demonstrated no PD-L1 expression, two
had expression on macrophages only, one showed less than 10% expression, and one
had greater than 20% PD-L1 expression (Table 4.1). Three of those seven patients
exhibited objective response to nivolumab treatment (i.e. >6 cycles of therapy); however,
response was not correlated with PD-L1 expression. The patients that exhibited a
positive tumor PD-L1 expression had a histology of squamous cell carcinoma. The
patient whose sample had a PD-L1 expression greater than 20% had a history of chronic
inflammatory conditions while the patient with tumor PD-L1 expression less than 10%
did not have a history of chronic inflammatory conditions.
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Table 4.1: PD-L1 expression and history of inflammation for nivolumab-treated NSCLC
patients.

Histology

Response on
Nivolumab

Inflammatory
Disease

F

adenocarcinoma

NR-expired

yes

BH2022

F

R

yes

BH2023

M

adenocarcinoma
squamous cell
carcinoma

PD-L1
expression by
IHC
macrophages
only
macrophages
only

NR-expired

no

<10%

BH2024

F

adenocarcinoma

Lost to follow-up

no

no

BH2025

F

Lost to follow-up

no

no

BH2026

M

adenocarcinoma
squamous cell
carcinoma

NR-expired

yes

~20%

BH2027

F

N/A

NR-expired

yes

no

Patient
ID

Gender

BH556
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Outcome Data Results
The health outcomes research aim provided a much larger pool of patients to assess.
Table 4.2 displays the baseline demographic and clinical characteristics of the study
population by exposure group. Eligibility criteria were met by 3,252 ICI-treated patients
from whom a complete dataset was available. Among the ICI-treated cancer patients
identified, 2,339 had a history of chronic inflammation and 913 patients did not. There
were 432 patients who passed away within one-year of diagnosis. The mean age of
patients in the chronic inflammation cohort was 62.3 (SD = 12.31) and in the no chronic
inflammation cohort was 52.6 (SD=12.72). In both exposure groups, melanoma and lung
cancer were the only two diagnosed cancers, and the majority of patients were diagnosed
with melanoma (lung cancer = 815 and melanoma = 2,612 patients). Over 95% of the
entire patient population was previously treated with cytotoxic chemotherapy. Of the
chronic inflammation cohort, 42% were treated previously with radiotherapy whereas 36%
of the no chronic inflammation cohort was treated with radiotherapy. In the chronic
inflammation cohort, 1,987 were obese, 1,761 were diagnosed with diabetes, 609 with
hypertension, 854 with hyperlipidemia and 1,582 with COPD.

The number of matched pairs post-propensity score matching were 1,948 for the chronic
inflammations versus no chronic inflammation comparison. Upon stratification by cancer
type, the number of matched pairs for lung cancer and melanoma were 367 and 1,531,
respectively. While baseline differences existed among exposure groups, matching
provided samples that had minimal differences (Table 4.3). Four clinical variables
(myocardial infarction, congestive heart failure, peripheral vascular disease and
cerebrovascular disease) did not meet standardized differences scores below 0.10, that
which is accepted to be balanced between cohorts. To account for these differences,
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these four variables were included as covariates in the Cox proprotional hazard regression
model. Table 4.4 displays the HR and associated 95% CI for the effect of the exposure
group on on-year survival within the propensity-matched sample. Pre-existing chronic
inflammation improved overall survival compared to no history of chronic inflammation
(HR 1.23, 95% CI 1.01-1.50). When stratified by cancer, this observation held true
specifically in patients with melanoma (HR 1.26, 95% CI 1.01-1.58). No differences were
observed in patients diagnosed with lung cancer (HR 1.35, 95% CI 0.82 – 2.23).
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Table 4.2: Baseline demographics for all immune checkpoint inhibitor treated patients.

Chronic Inflammation
Mean
Std. Dev
Age
CCI
Gender (M)
Urban
CCI Category
1
2
3
4
Obesity
Diabetes
Hypertension
Hyperlipidemia
COPD
Myocardial Infarction
Congestive Heart Failure
Peripheral Vascular
Disease
Cerebrovascular Disease
Dementia
Rheumatism
Peptic Ulcer Disease
Mild Liver Disease
Paralysis
Renal Disease
Cancer
Severe Liver Disease
Metastatic Cancer
HIV/AIDS
Lung Cancer
Melanoma
Previous Chemotherapy
Previous Radiation

62.3
9.65
N (2,339)
1518
398
2,339
37
67
48
2187
1987
1761
609
854
1582
140
229

12.31
2.4
%
64.9%
17.0%

657
705
145
53
56
713
69
189
2325
19
2,184
7
679
1,839
2,272
971

79

No History
Mean
Std. Dev
12.72
2.6
%
54.2%
15.9%

1.6%
2.9%
2.1%
93.5%
85.0%
75.3%
26.0%
36.5%
67.6%
6.0%
9.8%

52.56
7.63
N (913)
495
145
913
113
13
8
779
0
0
0
0
0
5
8

28.1%
30.1%
6.2%
2.3%
2.4%
30.5%
2.9%
8.1%
99.4%
0.8%
93.4%
0.3%
29.0%
78.6%
97.1%
41.5%

73
114
26
19
8
209
16
4
876
3
783
3
136
773
863
330

8.0%
12.5%
2.8%
2.1%
0.9%
22.9%
1.8%
0.4%
95.9%
0.3%
85.8%
0.3%
14.9%
84.7%
94.5%
36.1%

12.4%
1.4%
0.9%
85.3%
0.0%
0.0%
0.0%
0.0%
0.0%
0.5%
0.9%

Table 4.3: Standardized differences post-propensity score matching.

Obs
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

Cohort (Chronic Inflammation)
Variable
Age
Charlson Comorbidity Index (CCI)
Gender
Region
Urban
CCI Category
Myocardial Infarction
Congestive Heart Failure
Peripheral Vascular Disease
Cerebrovascular Disease
Dementia
Rheumatism
Peptic Ulcer Disease
Mild Liver Disease
Paralysis
Renal Disease
Cancer
Severe Liver Disease
Metastatic Cancer
HIV/AIDS
Chemotherapy
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Std. Diff
0.117
0.517
0.035
0.050
0.046
0.159
0.231
0.298
0.299
0.228
-0.011
-0.006
0.003
0.024
0.021
0.021
0.021
0.021
0.021
0.021
0.0722

Table 4.4: One-year survival analysis for ICI-treated patients. Hazard ratios (HR) and
associated 95% confidence intervals (CI) for the impact of chronic inflammation on
survival within the propensity-matched sample. Results include entire treated group (All
Selected Cancers) and stratified by cancer type.

Stratification
All Selected
Cancers
Lung
Melanoma

Patients with
History of
Chronic
Inflammation

Patients without
history of
Chronic
Inflammation

HR

1,218

730

1.23

1.01

1.5

240
949

127
582

1.35
1.26

0.82
1.01

2.23
1.58
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95% CI

D. DISCUSSION

ICIs have been enthusiastically accepted by clinicians as a promising option for patients
well into their malignancy treatment pathway. PD-1 inhibitors such as nivolumab and
pembrolizumab are gaining additional FDA approvals for several malignancies, including
becoming first line treatment options in metastatic disease (216). The high financial
costs of these agents justify careful consideration when selecting a patient to be treated.
The one guiding principle presently used clinically is PD-L1 expression on tumors. This
diagnostic has inherent flaws and has not been able to objectively determine patients
exhibiting long-term durable responses. Therefore, we undertook these studies with the
hypothesis that comorbid conditions, specifically those that affect the inflammatory
conditions in the periphery and in the tumor microenvironment, would correlate with
response to nivolumab in NSCLC patients. Furthermore, closer examination of these
comorbid conditions, may allow us to identify a molecular signature going forward that
serves as a robust predictor of response. Our hypothesis is anchored in the concept that
while chronic inflammation may create genetic alterations that induce the growth of
tumor cells, the presence of those immune factors in peripheral blood, and in the tumor
microenvironment, may prime an immune response once the inhibition of the immune
checkpoint is released.

The first local, retrospective study presented herein identified an association of chronic
inflammatory conditions with the response of cancer patients treated with nivolumab.
Our patient population consisted of a small group of adult patients with metastatic
NSCLC disease who progressed after platinum chemotherapy. As expected, twenty
percent of our population exhibited long-term durable responses matching the results of
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other long-term nivolumab treatment studies. Patients with a history of chronic
inflammatory conditions, including metabolic syndrome disorders or COPD, stayed on
nivolumab therapy for a longer period averaging a higher number of cycles received. In
addition, those patients with a history of more than two of these conditions received an
average number of nivolumab cycles greater than those patients with only one condition.
Of the seven tumor samples analyzed for PD-L1 expression, two exhibited positive
expression and neither correlated with improved response. PD-L1 expression alone did
not correlate with response however the patient with PD-L1 expression greater than 20%
also had a comorbid history of chronic inflammation.

Components of the circulating immune response might better indicate response to ICI
agents than PD-L1 expression alone. Systemic inflammation has been shown to
increase oxidative stress, activate circulating neutrophils and lymphocytes, and alter
levels of inflammatory mediators (i.e. TNF-α, IL-6, IL-8 & C-reactive protein) (217, 218).
The tumor microenvironment may have altered levels of cytokines, growth factors, and
chemokines that affect tumor cell proliferation, survival and immune evasion due to
chronic inflammation (4). Chronic obstructive pulmonary disease (COPD), a chronic
inflammatory condition, is associated with elevated IFN-γ + and TNF-α+ CD8+ T-cells
when compared with healthy controls (219). TNF-α is recognized by two receptors, TNFα R-1 and TNF-α R-2, the latter of which is expressed mainly on immune cells (220). It
has been shown that high concentrations of this cytokine can induce an anti-tumor
response in sarcoma mouse models (221). In addition, NSCLC patients with elevated
TNF-α in tumor islets have had favorable survival rates (222). The interplay between
chronic inflammation and immune response has been theorized as an important part of
immune checkpoint inhibition (223, 224). PD-L1 expression can be induced by interferon
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(IFN) activity, and indirectly by IL-12, in both endothelial normal cells and breast cancer
cells (207, 208). Importantly, activated oncogenes can transduce intracellular signaling
events leading to aberrant PD-L1 expression in cancer cells (225). Taube and
colleagues investigated the signaling events that induce PD-L1 expression and
demonstrated that many cytokines were overexpressed in melanoma cell lines, including
RANTES, CXCL1, IL-10, IL-18 and IL-21. In vitro stimulation of melanoma cells by IFN-γ
induced PD-L1, but recombinant forms of the other cytokines failed to increase cell
surface expression of PD-L1 with or without IFN-γ (54). However, incubation of activated
T-cells with IL10 (+/- IFN-γ) induced expression of PD-L1 on monocytes thereby
reducing T-cell activation (51). In an open-label, phase 2 randomized controlled trial,
patients with NSCLC who progressed post-platinum chemotherapy were allocated to
treatment with atezolizumab (PD-L1 inhibitor) or docetaxel (75). In an exploratory
analysis, effector T cell INF-γ gene signatures, defined by CD8A, GZMA, GZMB, IFNγ,
EOMES, CXCL9, CXCL10, and TBX21 were assessed. Patients with high expression of
the IFN- γ signature had improved overall survival with atezolizumab treatment
compared to patients with low expression of this cytokine gene signature (HR 0.43, 95%
CI 0.24-0.77).

Our second aim was an observational cohort study and identified a significant effect on
the overall survival of cancer patients who received immune checkpoint inhibitor
treatment with previous comorbidity of a chronic inflammatory condition, replicating the
institutional study. Upon stratification by cancer type, the improved survival advantage
held true only in the melanoma population. Our Truven population of ICI-treated patients
were identified from early 2011 to the end of December 2015. The earliest FDA approval
of an ICI for the treatment of lung cancer was granted to nivolumab on March 4th, 2015
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for the treatment of metastatic squamous NSCLC with progression on or after platinumbased chemotherapy (184). This limited our follow-up and none of these patients
completed one full year of follow-up to assess one-year mortality. Thus, additional years
of data are necessary to fully vet the lung cancer population for the effect of chronic
inflammation on response to ICI. This population suggests however that chronic
inflammation does impact overall survival for ICI-treated patients. This health outcomes
study improved and extended the results of the prior analysis with the inclusion of a
large sample size and with the use of one-year overall survival as a measure of
response.

Limitations of the local retrospective study include the small population size as well as
the use of cycles of nivolumab therapy as a surrogate for survival. The population size
assessed in this study is 45 patients, which is enough to assess trends and correlations,
but a much larger sized population of real patient data will be required to validate the
findings of this study. Clinically, response is measured by two outcomes, PFS and OS,
each allowing direct interpretation of how ICIs affect the tumor size and growth. Cycles
of therapy, although may reflect the length of the treatment period and tolerance of the
regimen, does not give us insight on the effect of ICIs on the tumor. The national health
outcome study is subject to the limitations of all claims-based studies (182, 183). Claims
data lack detailed information on laboratory values or tumor staging, which may have
influenced the outcomes of this study. This study was limited to a one-year follow-up due
to the availability of data. Lastly, while propensity score matching is known to reduce
selection bias in non-randomized studies, it is possible that residual bias is present or
that unmeasured confounders may have impacted these findings (158). This study is
strengthened by a large sample size and the assessment of all-cause mortality.
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Obesity and Inflammation
Obesity is a worldwide epidemic which is characterized by inflammation of adipose
tissue eventually leading to the development of type 2 diabetes, cardiovascular disease
and cancer (226). Immunologically, adipocytes represent a large source of immune cells
and inflammatory cytokines including T cells, B cells, macrophages and neutrophils
(227). The number of leukocytes in the blood is increased as compared to patients with
a normal body surface area (BSA) (228). Monocytes, specifically macrophages, migrate
to adipose tissue and overwhelming have an M1 configuration relative to M2, leaning
into a pro-inflammatory function (229). The increased release of leptin from adipocytes
of visceral fats act upon Th1 and Th2 cells inducing the production of IL-2 and IL-4
activating the proliferation of T cells (230). In addition to the release of leptin, resistin and
visfatin induce the production of IL-1β, IL-6, IL-8 and IL-12 (231). Adipose tissue from
obese patients with colorectal cancer expressed elevated levels of PD-L1 and PD-L2
(232). The presence of adipose tissue from obese patients that is present throughout the
development of the tumor may instill a pro-inflammatory tumor microenvironment. The
adipose tissue surrounding the tumor site would potentially secrete the same cytokines
and induce the immune cell populations present in the periphery as well.
Diabetes and Inflammation
Obesity is closely linked to the advent of type 2 diabetes mellitus (T2DM) which itself is
associated with several macrovascular (coronary artery disease, stroke) and
microvascular complications (diabetic retinopathy, nephropathy and neuropathy) (233).
In an analysis of inflammatory cytokine concentrations from monocytes and neutrophils
in patients with T2DM, it was observed that the concentrations of TNF-α, IL-6, IL-1β, IL10, IL-12, IL-8, IFN-β and IFN-γ were all normal compared to non-diabetic volunteers
(234). However, when assessing the gene expression, cytokine and TLR gene profiles
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were enhance in T2DM patients compared to non-diabetic volunteers. TNF-α, IL-6 and
IFN- β mRNA levels in monocytes and neutrophils were elevated in patients with good
glycemic control however patients with poor glycemic control presented with a reduced
inflammatory expression and did not differ from the non-diabetic volunteers. Genomewide expression profiling of patients with diabetes shows an up-regulation of CD274,
otherwise known as PD-L1 (235). This is to prevent the pancreatic islets from
autoimmune destruction but may be allowing for the up-regulation of PD-L1 on tumors
increasing the likelihood of success with ICI therapy. The control of the diabetic state
also directly influences the inflammatory environment. The diagnosis alone of diabetes
prior to ICI therapy may not be a robust measure of predicting response without the
assessment of glycemic control.
COPD and Inflammation
COPD is typically caused by exposure to inhaled toxins such as tobacco smoke or dust
and has been deemed a risk factor for the development of lung cancer. Just like with
T2DM, the severity of COPD dictates the inflammatory cytokines present in the lung
(236). IL-6, IL-8 and IL-10 were independently associated with worse airflow obstruction
(P<0.05). In a full regression model with all clinical covariates including IL-2, IL-6, IL-8,
IL-10, TNF-α and INF-γ, IL-6 accounted for the largest portion of the variance of forced
expiratory airflow at 1 sec (FEV1%). In a cohort of 10,300 COPD patients, blood was
drawn and spun down during their initial visit and then again in their 5-year follow-up visit
(237). Elevated IL-6 was associated with rapid decline of airflow at 5 years. This
observations held despite stratification by COPD treatments used. In malignancies, IL-6
was seen to play a part in tumor microenvironment regulation and the induction of
metastasis through down-regulation of E-cadherin (238, 239). IL-6 exposure in cervical
carcinoma cell lines induced IL-6R and STAT3 expression resulting in the down87

regulation of E-cadherin. IL-6 complexes with IL-6R then associated with signaltransducing membrane protein gp130. GP130 dimerization occurs and is followed by
rapid activation of the Janus kinase (JAK) family. Activated JAKs then phosphorylate
tyrosine residues on the receptor. Signal transducer and activator of transcription
proteins (STATs) with SH2 domains are recruited to the receptor where they are
tyrosine-phosphorylated by JAKs. The activated STATs then dimerize and translocate to
the cell nucleus where they induce transcription of target genes. STAT3 activation
suppresses Toll-like receptor 4 (TLR4) ligand and lipopolysaccharide (LPS)-mediated
dendritic cell (DC) maturation and activation (240). In addition, STAT3 activation by IL-6
suppresses MHC class I expression on DCs and attenuates CD4+ Th1 helper T cell
response through activation of lysosomal protease (241). Th1 cells produce IL-2 and
IFN-γ which are involved in the activation of cytotoxic T lymphocytes (242).
Augmentation of IFN-γ levels directly impact PD-L1 expression on tumor cells (243).

E. CONCLUSIONS
Our data show that a patient history of chronic inflammation correlates with ICI
response. In an institutional IRB-approved study, former and current NSCLC patients
treated with a PD-1 inhibitor were assessed for a correlation between their history of
chronic inflammation and ICI response, and those with a history of at least one chronic
inflammatory condition received more cycles of nivolumab therapy than those patients
who did not have these conditions. Using the national health outcomes data, our work
shows that patients with a history of chronic inflammatory comorbidities have improved
one-year survival rates as compared to ICI-treated patients without a history of chronic
inflammation. These results are in accordance with the findings of the single-center
retrospective study.
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CHAPTER 5
A. OVERVIEW

My work that determined that cancer patients with a history of a chronic inflammatory
condition improves the response to immune checkpoint inhibitors (ICIs) was an initial
step in the development of a blood-based biomarker of response to ICI therapy.
Currently in clinical practice, the gold standard for isolating samples to develop
biomarkers of response in cancer is tumor tissue analysis. It is amenable to many
measures of biological activity including nucleic acid sequencing and assessment of
protein expression by immunohistochemistry (IHC) (244). Characterization of the tumor
specimen, from a biopsy or from resected material, can measure molecular features
specific to the patient; however, it represents a static image and does not characterize
the dynamic changes to the tumor over time. Importantly, even though this snapshot is
rich in information, it does not represent the inter- and intratumoral heterogeneity of a
tumor (245). Further, logistical issues may prevent acquisition of tumor tissue. Eighty
percent of metastatic non-small cell lung cancer (NSCLC) patients have limited tissue
availability and up to 31% do not have accessible tissue at all (246) .The performance
status of NSCLC patients may not allow for interventional biopsy procedures at the
moment needed for biomarker evaluation (247). Considering the limitations of tumor
tissue, liquid biopsies have become more appealing as they are much more accessible
for sampling, amenable to serial sampling throughout treatment, and flexible for multiple
testing platforms (flow cytometry, ELISA, mass spectrometry, etc.). Liquid biopsies may
contain circulating tumor cells (CTCs), non-hematological cells with malignant features
encompassed in the tumor microenvironment, and cells of the immune system (248).
Large comparison studies that assess the equality of DNA analysis of CTCs and tumor
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tissue biopsies demonstrate that the liquid biopsy approach gives a faithful measure of
DNA features compared with tumor tissue (249, 250). In addition to CTCs and cells of
the immune response, sampling the periphery can also measure tumor-derived
exosomes, extracellular vesicles that contain cytokines present in the tumor
microenvironment. Serial sampling of the periphery using liquid biopsies permits tracking
of efficiency and toxicity of treatment allowing the oncologist to anticipate the most
effective subsequent treatments (251).

I believe that liquid biopsy of NSCLC patients can provide a sample(s) for development
of a biomarker of response to ICI that exceeds the performance of the companion
diagnostic (IHC for PD-L1 expression) for PD-1 and PD-L1 inhibitors. Development of a
robust biomarker of response can improve efficacy and control the cost of therapy in
patients who have few therapeutic options, like recurrent lung cancer patients. We
hypothesized that chronic inflammation creates an environment that promotes an antitumor immune response and the molecular marker of that response can predict an antitumor response in NSCLC patients to immune checkpoint inhibitors. The primary goal for
this study was to measure pro-inflammatory cytokine levels and immune cell subtype
populations in healthy subjects and patients with metabolic syndrome, chronic
obstructive pulmonary disorder (COPD), and NSCLC to develop predictive biomarkers of
response to PD-1 and PD-L1 inhibitors. We expect this work to also be impactful in
further understanding the biological role of chronic inflammation in response to ICI.
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B. METHODS

Patient Selection and Monitoring
We received institutional IRB approval for this clinical study to recruit patients diagnosed
with metabolic syndrome disorders (MetS; hyperlipidemia, hypertension, diabetes mellitus
or obesity), COPD or NSCLC. These cohorts were selected as COPD and MetS
populations are expected to have a high degree of chronic inflammation, healthy subjects
were expected to have no history of chronic inflammation and NSCLC to have a mixed
history. Healthy subjects were included in this study who did not self-report any of the
aforementioned conditions and history of smoking. All subjects/patients were aged 50
years or older. We will enroll 20 healthy subjects and 20 each of the MetS and COPD
cohorts. We will enroll 90 NSCLC patients. All patients enrolled are 50 years or older and
women will be postmenopausal. Enrolled patients were excluded if they exhibited flu or
cold symptoms or the use of antibiotics in the two weeks prior to clinic visit, diagnosis of
an autoimmune disorder or treatment with any immune modulating therapies or lastly,
smoking history (only for healthy volunteer cohort). All patients gave written informed
consent. The study protocol was approved by the institutional review board (IRB) of the
University of Kentucky. NSCLC cohort patients were recruited at the time of treatment with
a PD-1 or PD-L1 inhibitor. These included nivolumab, pembrolizumab and atezolizumab.
Blood samples were taken from patients with histologically confirmed NSCLC. Blood
samples were drawn right prior to ICI infusion. All NSCLC patients were monitored via
monthly (Months 1-3) and 3-month (Months 6, 9, and 12) chart review. Data collected
includes number of treatment cycles, CT scan results, objective response, patient survival,
and disease state measures (recurrence, progression, etc.). Durable response defined as
ongoing treatment with complete disappearance of all lesions or decrease in tumor burden
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by > 50% relative to baseline after 6 cycles of therapy per the immune-related response
evaluation criteria in solid tumors (irRECIST) (252).

Data Collection and Analysis
Enrollment of 20 subjects/patients of the healthy, MetS and COPD cohorts will provide
90% power to detect difference in expression of several inflammatory cytokines (see
power analysis below) using a two-sided, two-sample t-test with 1% significance
level. Adjustment in significance level was employed due to multiple comparisons
between healthy versus MetS and COPD cohorts. Frequency matching will be employed
to ensure similar distribution with respect to gender among the subject cohorts.
Assuming a moderate correlation coefficient equal to 0.30 between each cytokine level
and PD-L1 expression levels, enrollment of 90 NSCLC patients will provide 82% power
based on a two-sided t-test with 5% significance level.
Power calculations
Power was determined by reviewing the literature for evidence of whether physiological
levels of cytokines were significantly different among COPD and metabolic syndrome
patients, and healthy adults (e.g. IL-4, IL-5, and TNFα). From these reports, we
determined that a small sample size per group provide power to detect differences in
cytokine levels (253-255). Specifically, we will compare each cytokine level between
NSCLC and each of the MetS, COPD and healthy cohorts. Statistical power for the
NSCLC cohort was primarily based on the association of PDL1 expression with clinical
outcome and this will be carried out as an exploratory analysis. Other data analysis
plans include two group comparisons of each cytokine between healthy and each of the
MetS, COPD and NSCLC groups using two sample t-test, and analysis of variance
(ANOVA) for comparison across groups.
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Multiplexed ELISA
Consented patients had two blood samples drawn in 6-mL K2+EDTA+ in the clinic and,
those were transported to the lab. Each blood sample (10-12ml) was immediately
centrifuged at 250 g for 10 minutes at room temperature. The plasma from each patient
or normal donor was aliquoted in cryotubes and stored in -80C. Cytokine profiles were
assessed by multiplex human cytokine ELISA assay (Quansys Biosciences, Logan, UT,
USA) to determine the relative levels of 15 pro-inflammatory cytokines. The 15 cytokines
included were IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70, IL-13, IL-15, IL-17, IL23, IFN-γ, TNF-α and TNF-β. The multiplexed assay was used to reduce volume of
sample needed and to standardize the assay using purified cytokines as controls.
Cytokine concentrations were measured then calculated by Q-View software version
3.09. All samples were assayed in duplicate and the mean value was reported.
Flow Cytometry
Due to known degradation of cell surface markers such as PD-L1 when samples are
cryopreserved, flow cytometry was conducted promptly after blood sample collection
(256). Following plasma removal, the remaining blood sample was processed through a
Ficoll Hypaque gradient and centrifuged at 400 g for 20 minutes at room temperature to
separate plasma from the buffy coat which contains peripheral blood mononuclear cells
(PBMC) (257). Cells were washed twice in buffer (PBS). After PBMC isolation, 1 x 106
cells were distributed to 10 FACs tubes. Cells were pelleted by centrifugation,
resuspended in 400 μl of buffer (PBA). Cell suspensions were stained with
Phycoerythrin-conjugated anti-human CD279 (PD-1), fluorescein isothiocyanateconjugated anti-human CD3, phycoerythrin-cyanine 5-conjugated anti-human CD4,
phycoerythrin-cyanine 7-conjugated CD8, phycoerythrin-conjugated anti-human CD274
(PD-L1), fluorescin isothiocyanate-conjugated anti-human CD14 and allophyocyaninconjugated anti-human CD45 antibodies. Secondary antibodies for CD3, CD4, CD8,
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CD14, CD45, PD-1 and PD-L1 bound to fluorophores were added to FACs tubes and
incubated in cold room over 20 minutes. Immune cell subtype populations sorted using
the Attune™ flow cytometer. Immune cell populations analyzed included CD3+ only,
CD3+CD4+, CD3+CD8+, CD4+PD-1+, CD8+PD-1+, CD14+CD45+ and
CD14+CD45+PD-L1+. Flow cytometry data analysis was performed using FlowJo
version 7.6.5 (Tree Star).
Statistical analyses
Statistical analyses were conducted in collaboration with Katherine Thompson, PhD of the
Department of Statistics at the University of Kentucky. Distribution of continuous variables,
including cytokine concentrations and immune cell populations, were described by their
mean and standard deviation. Four cohort comparisons (Healthy, MetS, COPD, NSCLC)
were done using analysis of variance (ANOVA). A p-value < 0.05 was considered as
statistically significant. All analyses were performed using SAS software (SAS, Cary, NC,
USA) and R Package software (Version 3.40) (258). Cytokine concentrations, expressed
in pg/ml, were first assessed by Fisher’s exact test for detection in plasma. Cytokines that
were detectable were then compared by ANOVA followed by post-hoc t tests with
reference to NSCLC cohort. Cytokine concentrations were natural log-transformed.
Immune cell subtype populations derived from flow cytometry were compared using
ANOVA followed by post-hoc t tests with reference to NSCLC cohort. Percentages of
specific immune cell populations were transformed by taking the arcsine of the square root
for ease of depiction. ANOVAs followed by post-hoc t tests were used for assessment with
reference to NSCLC to determine if any cohort significantly differed in immune cell
subtypes. Finally, to determine whether immune cell subpopulations and/or cytokine levels
predict response to ICI in NSCLC patients, a logistic regression model was employed. It
is likely that this model would not be appropriate with these data due to perfect separation
of responders from non-responders, so feasible solutions algorithm (FSA) with the
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criterion of Bhattacharrya distance (B-distance) will be utilized to assess pairs of
observations that can provide “feasible solutions” for prediction of ICI response in the
NSCLC cohort (259-261). Perfect separation typically occurs in small samples with
unbalanced and/or highly predictive variables. Separation occurs if the predictor is
associated with only one outcome value when the predictor is greater than some constant
(262). This means the maximum likelihood estimate of the logistic slope coefficient does
not exist. FSA is a technique that allows the assessment of predictive capabilities of
different combinations of pairs of variables to determine the pair(s) with the best predictive
ability of the outcome of interest. This technique serially tests pairs based on a selected
criterion. FSA in turn can employ B-distance, a measure of the relative proximity of two
samples taking into account shape, range and direction of the sample data. The center
point of two samples may overlap, but when considering each individual data value, the B
distance may be different and highlight variables of interest.
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Figure 5.1: Clinical study protocol
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C. RESULTS

The study is ongoing and has recruited 36 patients to date, six in the COPD cohort and
ten in each of the remaining cohorts. The study will continue to achieve target accrual;
however, herein I discuss the interim analysis of the data collected. First, not all
cytokines could be detected (Detect: Y/N) from plasma using multiplexed ELISA (Table
5.1). Cytokines that were detectable in greater than 50% of the subject/patient samples
included IL-4, IL-6, IL-13, IL-23, IFN-γ and TNF-α. IFN-γ was evaluable in all patient
samples. Certain cytokines were more readily detectable in certain cohorts. IL-4
concentrations were detectable in most healthy subjects but not in any other cohort. IL-6
concentrations were detectable in patients with NSCLC and healthy subjects. Six
detectable cytokines were compared for differences among the cohorts (Figure 5.2). In
NSCLC patients, IL-4 levels were significantly decreased compared to the healthy
subject cohort (P=0.0066). In addition, the COPD cohort trended toward increased IL-4
concentrations compared to NSCLC patients (P=0.1888). IL-6 demonstrated lower
concentrations in the MetS cohort compared to the NSCLC cohort (P=0.0691). IL-13
levels are decreased in NSCLC patients compared to healthy subjects (P=0.0788).
Although IFN-γ was detectable in all patients, there were no significant differences
among the four cohorts. TNF-α did not show any significant differences among the
cohorts.
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Table 5.1: Cytokine measurements organized by cohort.

IL-1a (pg/ml)
IL-1b (pg/ml)
IL-2 (pg/ml)
IL-4 (pg/ml)
IL-5 (pg/ml)
IL-6 (pg/ml)
IL-10 (pg/ml)
IL-12p70 (pg/ml)
IL-13 (pg/ml)
IL-15 (pg/ml)
IL-17 (pg/ml)
IL-23 (pg/ml)
IFN-y (pg/ml)
TNF-a (pg/ml)
TNF-b (pg/ml)

Detect

Healthy

COPD

MetS

NSCLC
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Figure 5.2: Comparison of IL-4, IL-6, IL-13, IL-23, IFN-γ, and TNF-α levels by cohort.
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The second goal was to investigate the proportions of relevant immune cell subtypes in
each cohort and compare among cohorts. The immune cell subsets chosen for study
include CD8+ T cells, CD4+ T cells, CD14+CD45+ monocytes, PD-1+ T cells and PDL1+ monocytes. Lymphocyte populations were assessed using CD3, CD4 and CD8
markers. Monocyte populations were then assessed using the markers CD14 and CD45.
We found significant differences among the several cohorts (Figure 5.3). Healthy
subjects, patients diagnosed with MetS, and those with COPD all had significantly
elevated levels of CD3+ lymphocytes compared to patients with NSCLC (P=0.0094,
P=0.0043, P=0.0026, respectively). There were no detectable differences between
CD3+CD4+ lymphocyte populations among all four cohorts; however, there was a
significantly increased level of CD3+CD8+ lymphocytes in the NSCLC cohort compared
to both healthy subjects and MetS patients (P=0.0344, P=0.0099, respectively).
Interestingly, the CD3+CD8+ immune cell subtype did not differ between NSCLC and
COPD patients. There were no distinguishable differences in CD4+PD-1+ or CD8+PD1+ populations among the cohorts. Of note, monocyte populations were significantly
elevated in patients with NSCLC compared to the MetS and COPD cohorts (P=0.0293,
P=0.0025, respectively). However, the comparison of CD4+CD45+PD-L1+ immune cell
subtypes showed no difference among cohorts.

Finally, we examined whether any of the measured parameters might predict durable
response to ICI in the NSCLC cohort. Of the ten patients in the NSCLC cohort, seven
met our criteria for durable response. Eleven variables were selected to be included in a
logistic regression model; six cytokines (IL-4, IL-6, IL-13, IL-123, IFN-γ, TNF-α) and 5
immune cell populations (CD3+ Only, CD3+CD8+, CD8+PD-1+, CD14+CD45+,
CD14+CD45+PD-L1+). Logistic regression models could not be fit due to perfect
separation between the 7 responders and 3 non-responders. In this case, all durable
101

responders are associated with a cytokine concentration above or below a certain level.
For maximum likelihood estimates to exist, there must be some overlaps in the two
distributions. We then used FSA, with a criterion of B distance, to find possible solutions
that might be predictive. Out of 25 times FSA was run, two pair of measures were
determined to be predictive of response (Figure 5.4A). The combination pair of CD3+
only and CD8+PD-1+ immune cell populations had the largest B distance of 2.88. This
pair was chosen 15 of the 25 trials. Elevated CD8+PD-1+ populations and low CD3+
only populations were predictive of non-responders (Figure 5.4B). Another pair was
chosen for the remaining 10 trials and that is the combination pair of CD14+CD45+
monocyte population and IFN-γ cytokine concentration with a B distance of 2.34.
Increased concentrations of IFN-γ and elevated monocyte populations were indicative of
response (Figure 5.4C).
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Figure 5.3: Comparison of immune cell populations by cohort.
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Figure 5.4: Feasible solutions algorithm (FSA) assessment to predict durable response in NSCLC cohort.
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D. DISCUSSION

Recent literature has revealed that the presence of inflammatory cells within the tumor
microenvironment is associated with an improved clinical outcome after treatment with
ICIs (263). The concept of “immune contexture” was established, assessing the type,
density, functional orientation and location of the immune cells within distinct tumor
regions (264). To establish a viable clinical utility for this concept in ICI-treated patients,
the immunoscore was formed that is based on the immune cell subtype populations. The
immunoscore can be based on any combination of the lymphocyte or monocyte
populations but most researchers noted the use of CD3+ and CD8+ tumor-infiltrating
lymphocytes (TILs).

To date, there has been no standardized scoring system of immune cell profiles
combined with cytokines concentrations from peripheral blood to predict response from
ICI treatment in NSCLC patients. Our goal was to use our prior work that established
that chronic inflammation associates with response to PD-1 and PD-L1 inhibition and
extend that work to measure molecular markers of inflammation, specifically
inflammatory cytokines and immune cell subsets in the periphery of patients with known
chronic inflammation or NSCLC. The inclusion of healthy, MetS and COPD cohorts was
to compare different states of known chronic inflammation to the mixed state expected
within the NSCLC cohort with the expectation that NSCLC patients that are responders
to ICI would have an immune profile similar to those with chronic inflammation. We
sought to determine whether peripheral biomarkers could also predict response to ICI
therapy in NSCLC and whether the inflammatory markers are different in NSCLC
compared with other cohorts of non-cancer, chronically inflamed patients.
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While this study is ongoing, preliminary analysis of the data has provided insights into
the molecular interactions of immune response and cancer. The primary endpoints
analyzed are the differential expression of cytokine concentrations and immune cell
subsets in NSCLC patients compared to patients with MetS or COPD. In our exploratory
analysis, we have shown that immune cell subtype populations consisting of elevated
CD3+ lymphocytes as well as low CD8+PD-1+ T cells, which distinguishes an exhausted
cytotoxic T cell population, were predictive of response in NSCLC. CD3 is a T cell coreceptor present on both T helper cells and cytotoxic T cells and is a general indicator of
proliferation of lymphocytes (265). Elevated CD3+ expression suggests that the
proliferative status of the immune response in NSCLC patients may indicate a readily
actionable response to tumor cells following inhibition of the co-inhibitory signal. Low
PD-1 expression on CD8+ cells has previously been shown to be a distinctive feature of
nivolumab-treated patients showing clinical benefit with prolonged progression-free
survival (HR 4.51; 95% CI 1.45-13.94) (266). With the development of PD-1 inhibitors
that bind directly to the PD-1 receptor, it was hypothesized that the more PD-1
expressed on T cells, the more anti-PD-1 antibody binding will occur. However, it is likely
that elevated PD-1 expression indicates an exhausted state that, even with the binding
of anti-PD-1 antibodies, the cytotoxic T cells cannot surmount a strong immune
response to the tumor cells. With the variability of PD-L1 expression, PD-1 negative
effector T lymphocytes provides an immune-privileged microenvironment with a positive
impact on survival.

We also identified a second combination of predictive markers, consisting of an immune
cell subtype population and concentration of a certain cytokine was also predictive of
response: increased CD14+CD45+ macrophage populations and IFN-γ concentrations.
These results suggest activation of the innate immune response in NSCLC patients that
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respond to ICI therapy. Specifically, innate immune response includes the activation of
macrophages and the boosting of natural killer cell activity. Inflammatory monocytes
selectively traffic to the sites of inflammation, produce inflammatory cytokines and
contribute to local inflammation (267). CD14+ monocyte count increases correlate with
presence of inflammatory conditions. Antitumor M1-polarized macrophages have the
ability to direct cytostatic and cytotoxic effects on tumor cells, secret pro-inflammatory
cytokines, and stimulate T cell immunity (268, 269). Investigations into the cooperation
of lymphoid cells and macrophages led to the identification of IFN-γ as a regulator of
macrophage tumoricidal activity (270). Two molecular signals are required for efficient
induction of the M1 phenotype, TLR4 agonist LPS and IFN-γ (271). Importantly, IFN-γ
has been identified as a cytokine that specifically upregulates PD-L1 expression on
tumor cells, but it also plays a key role in the PD-L1 expression on macrophages.

Completion of this study is required to ascertain whether these pairs of peripheral
immune properties significantly predict responders to ICI treatment. Once accrual to all
cohorts is complete, a validation cohort study will be required to compare the precision
of this assay compared to the current standard of care, PD-L1 expression in the tumor.

E. CONCLUSION
Preliminary analysis of peripheral cytokine profiles and immune cell subset populations
has identified several immune response molecular markers that describes differences
among inflamed patients and healthy subjects and may be effective in predicting
response to ICI therapy in NSCLC patients. We have shown that IL-4, IL-6, IL-13, IL-23,
IFN-γ and TNF-α are detectable in peripheral blood. The cytokine profile present in
NSCLC patients closely resembles that of COPD patients. Immune cell subset
populations, including those with PD-1 receptor or PD-L1 can be assessed from PBMC
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however there were no significant differences among cohorts. These data have given us
insight into the alteration of the innate and adaptive immune responses that may be
important for response to immune checkpoint inhibition. Importantly, these markers were
generated from a minimally-invasive sample from peripheral blood and could be readily
used by clinicians to continually monitor the patient for response and toxicity. Complete
analysis of the entire study population will be required to confirm these findings and
extend these observations.

Copyright © Sherif M. El-Refai 2017
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CHAPTER 6
A. SUMMARY OF RESULTS

By coupling an observational clinical study design with a pharmacoepidemiological
analyses, I have developed a testable hypothesis that chronic inflammation predicts
response to ICI treatment in NSCLC patients. I then hypothesized that a liquid biopsy
could be used to generate a biomarker of response to immune checkpoint inhibitors (ICI)
in NSCLC patients by measuring molecular markers of inflammation. I concluded this
work by demonstrating that this strategy could be utilized for the development of a
peripheral blood biomarker assessment to predict response to ICI treatment.

The first hypothesis that chronic inflammatory comorbidities, explored in Chapter 4, was
tested by utilizing health outcomes research and pharmacoepidemiology principles to
address the direct impact of chronic inflammatory comorbid conditions on response to
ICI treatment without respect to a particular cancer. I developed an experimental
strategy to identify a novel biomarker of response to ICI therapy. I initially utilized these
principles to test hypotheses using large national databases based on the impact of
treatment or exposure on specific biological pathways and processes. Specifically, in two
previous studies, I measured the impact of statin therapy on survival in cancer and then
in the next study, calculated the incidence of autoimmune diseases in lung and renal
cancer patients (108, 272). In the study outlined in Chapter 4, I found that, among the
3,252 ICI-treated patients between 2011 and 2015, 2,339, with a history of chronic
inflammation, had an improved one-year overall survival compared to those without
chronic inflammation. This observation was in agreement with the findings of our local
retrospective study analysis. Those results suggest that comorbidities that elicit a
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constant, low-grade inflammatory state have a positive impact on the patient response to
ICI treatment. It is anticipated that through further analysis and validation, the immune
cell and cytokine profile brought about by this low-grade inflammatory state will yield a
predictive diagnostic, achieved by liquid biopsy, to identify responders to ICI treatment in
lung cancer.

In Chapter 5, I analyzed inflammatory cytokine concentrations and immune cell
populations in peripheral blood mononuclear cells (PBMCs) sampled from peripheral
blood of non-small cell lung cancer (NSCLC) patients and identified differences among
cohorts with and without inflammation and/or NSCLC and molecular profiles that may be
predictive of response to ICIs. I characterized the inflammatory profile of NSCLC
patients treated with programmed death receptor 1 (PD-1) or programmed death ligand
1 (PD-L1) inhibitors and compared to the profile present in patients with chronic
inflammatory disorders, either metabolic syndrome (MetS) or chronic obstructive
pulmonary disorder (COPD). I was able to identify six cytokines from peripheral blood in
all cohorts including interleukin 4 (IL-4), IL-6, IL-13, IL-23, IFN-γ and tumor necrosis
factor alpha (TNF-α) that were expressed above baseline. Of the six differentiallyexpressed cytokine, significant differences were observed between certain cohorts. The
cytokine profile of NSCLC most closely resembled that of the COPD cohort. NSCLC
patients exhibited a smaller population of CD3+ lymphocytes relative to the other
cohorts. Cytotoxic T cell (CD8+) levels in the NSCLC cohort were elevated compared to
healthy and MetS populations, but did not differ from the COPD population. In addition,
patients with NSCLC had a higher concentration of monocytes compared to MetS or
COPD patients. Of these observations, I identified two pair of peripheral blood markers
that may be predictive of response to ICI treatment; high CD3+ lymphocyte and low PD1 + cytotoxic T cell population levels or high monocyte levels coupled with high IFN-γ
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concentrations. Finally, these results suggest that the peripheral blood can provide a
means for minimally-invasive assessment of the state of the innate and adaptive
immune response that may serve as a predictor of response to ICIs. This enables
clinicians to sample for the predictor immune response from a peripheral blood test right
prior to ICI treatment and determine whether this treatment path is suitable for this
patient. Extending these observations to a more complete understanding of the
underlying mechanisms that influence patient response to immunotherapies including
ICIs will help shape future targeting strategies of the immune response.

A. EXPERIMENTAL CONSIDERATIONS

I utilized health outcomes data analysis to drive the design and analysis of the
observational clinical study to test the central hypothesis that peripheral blood markers
could be used to select patients primed for durable response for ICI therapy. Using
health outcomes approaches, we were able to assess specific health outcomes from a
large national population and make broad inferences about the underlying interaction of
cancer and chronic inflammation. Incorporating pharmacoepidemiology allowed us to
then focus on specific properties of chronic inflammation to analyze in the clinical study.
Finally, the use of clinical study model allowed us to directly explore the impact of
specific cytokine levels and of immune cell populations in a prospective manner in
patients undergoing therapeutic interventions.

Although the interim results are promising, it is important to note that the clinical study
has not met accrual goals and is thus not powered to address our central hypothesis that
chronic inflammation improves the response to ICI treatment in NSCLC patients.
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Completion of patient enrollment and peripheral blood assessment will be needed to
identify the appropriate immune markers to further validate in future studies.
Health Outcomes Data Models
National healthcare claims data from Truven Marketscan were used in these analyses.
This data encompasses both commercial and Medicare claims for over 65 million
patients across the United States. Due to the limited history of ICI use in clinical practice,
analysis of “big data” allowed us to study a large population of patients who otherwise
would not be evaluable. However, these data are limited to what is billed per claim for
each patient visit. Pathology of tumors and diagnostic laboratory values, which are not
present in the dataset, would allow for further insights into the underlying molecular
mechanisms. Importantly, health outcomes research is understood to identify
correlations as opposed to causation. Thus, continued validation in human peripheral
blood samples will be important for further development as a useful clinical biomarker of
response.
Prospective Clinical Study Model
We used a single site for prospective evaluation of biological markers of immune
response from peripheral blood. There are important considerations associated with
conclusions drawn from this clinical study. Peripheral blood samples were drawn only
once prior to treatment limiting the analysis to a single measure of cytokine
concentrations and immune cell populations. Also, peripheral blood concentrations of
cytokines are notably less than within the tumor microenvironment (255, 273, 274). Of
note, blood was drawn from a central line in NSCLC patients however was drawn by
venipuncture in the other cohorts. Blood drawn by venipuncture may introduce
inflammatory mediators not present from a central line blood draw. In order to reduce the
impact of these limitations, we performed all ELISA experiments using a multiplexed kit
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with the lowest level of detection (LLD) on the market. Although the kit allowed for levels
of 15 different cytokines, only 6 could be ascertained above the LLD.

Another experimental consideration in the prospective clinical study is the lack of PD-L1
expression data on the tumor from prior biopsies of the included NSCLC patients. A
comparison of the predictive ability of the peripheral immune profiles identified in this
clinical study to the clinical assessment of PD-L1 would have aided in determining the
value of the peripheral blood analysis. PD-L1 status is not routinely ordered for patients
to be treated with a PD-1 or PD-L1 inhibitor in the clinic. To address this limitation, we
assessed PD-L1 status expressed on PBMC in peripheral blood as a surrogate as it has
been previously shown to be readily detectable from peripheral blood (275).

B. CONTRIBUTION TO THE FIELD

This work makes a substantial contribution to an improved understanding of immune
checkpoint inhibition and immune response to cancer. The rising costs of
immunotherapy treatment are a burden for patients to bear. The identification of effective
ways of minimizing non-beneficial medication use and maximizing outcomes would aid
in their decision to proceed with treatment. Our work and the work of others have
identified multiple potential peripheral blood-sampled biomarkers that could underlie
responsiveness to ICIs (93, 94, 99, 102-104, 276). (see also Chapter 1). In a study by
Farsaci et al, peripheral immunoscores were established from analysis of PBMC prior to
treatment with vaccine therapy to prostate specific antigen (PSA) to define whether there
was a correlation of what with efficacy of immune-based treatment (87). Their approach
similarly assessed PBMC for immune cell populations but did not assess cytokine
concentrations from plasma. In addition, the Farsaci, et al. study did not assess a
113

peripheral immunoscore prior to the use of ICIs. Importantly, their study was able to
identify a peripheral immunoscore capable of predicting improvements in progressionfree survival (PFS). Martens et al explored combinations of 28 potential biomarkers
sourced from peripheral blood prior to cytotoxic T lymphocyte antigen-4 (CTLA-4)
inhibitor (88). A six-candidate combination biomarker was identified to be predictive of
improve overall survival; low LDH count, elevated eosinophils, low absolute monocytes,
high absolute lymphocytes, low Lin−CD14+HLA-DR-/low myeloid-derived suppressor cells
(MDSC), frequencies, and elevated CD4+CD25+FoxP3+ Treg frequencies. Similarly to
Farscai et al, this study did not evaluate cytokine concentrations. Another difference is
the assessment of baseline markers prior to anti-CTLA-4 treatment in melanoma
patients whereas our focus was on anti-PD-1 or anti-PD-L1 treatment in NSCLC
patients.

To our knowledge, our study is the first to identify potential biomarkers of response to ICI
therapy utilizing health outcomes research data. Our own mining of this dataset was
successful in identifying chronic inflammation as a precursor to durable response. I have
shown that the analysis of national patient data can be used to inform biomarker
characterization and drive clinical study design, limiting the expensive cost of large
prospective adequately-powered clinical trials. This concept of using health outcomes
data principles to drive translational research efforts remains to be rigorously tested, but
provides a hypothesis to be further explored by those in the field.

C. TRANSLATIONAL AND CLINICAL RELEVANCE

The findings presented in this work are fully translatable for clinical application. Each of
the formulated hypotheses and aims in this work were made with particular concern for
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their impact on patient care. Furthermore, the approaches used bridged both basic
science and clinical fields, thus being largely translational in nature.

Improving the methods by which appropriate patients are selected for treatment with ICIs
can properly balance cost-efficiency of this class of medications in the clinic. The cost of
nivolumab treatment is estimated to be greater than $100,000 per year due to the
continuous administration schedule (277). The median PFS of 9 months or longer,
depending on the agent used, may be worthwhile for durable responders but the cost
may be too great for those patients that gain little to risk no benefit. The impact of failed
treatment on health care costs, quality of life, and outcome are driving forces in the focus
on predicting response to cancer therapies. I have made a significant effort in
understanding the relationship of inflammation and response to ICI therapy in a clinical
setting, but more validation is necessary prior to implementation into practice. The
ongoing clinical study requires completion with accrual targets for all cohorts to firmly
assess significance of results in an appropriately powered cohort study. If our findings of
the two combination pairs of peripheral immune data remain predictive of response, a
prospective validation study will be conducted to affirm their utility. Translating our
findings to a clinically useful diagnostic is difficult, but addresses the broader clinical
needs of the health care system. Successful implementation of the model could
significantly impact health care costs and outcomes associated with ICI use.

One common practice utilized in anti-cancer therapy is the implementation of drug
combinations to combat resistance and to synergistically improve outcomes compared to
each agent separately. The probability of a tumor cell becoming resistant to a
combination therapy of two agents with differing mechanisms of action is far less than

115

the probabilities of the development of resistance to each individual agent alone (278,
279). If patients, at baseline, do not have the immune profile deemed as predictive as a
response, a secondary agent could be used to “prime” the patient’s immune profile to
become responsive to ICI therapy. Thus, identifying effective drug combinations for
treating NSCLC is paramount.

D. CONCLUSIONS

I conclude that chronic inflammation can be defined by a specific immune profile
consisting of cytokines and immune cell populations and believe that chronic
inflammation is predictive of response to ICI in NSCLC. This profile could aide in
identifying and stratifying NSCLC patients who will benefit from ICI therapy. Enrichment
of the treated population for responders will significantly impact the clinical utility of these
agents. The research methods employed here allowed us to characterize potential
biomarkers from peripheral blood without the cost of a large prospective clinical study.
Furthermore, we conclude that coupling bioinformatics principles with basic science
experimental approaches can bridge the gap of understanding of translating findings to
clinical application.

Copyright © Sherif M. El-Refai 2017
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